

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12N 1/20, 15/00, C07H 21/04	A1	(11) International Publication Number: WO 99/07828 (43) International Publication Date: 18 February 1999 (18.02.99)
(21) International Application Number: PCT/US98/16613 (22) International Filing Date: 10 August 1998 (10.08.98) (30) Priority Data: 60/055,451 11 August 1997 (11.08.97) US (71) Applicant (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): WARMKE, Jeffrey, W. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). ETTER, Adrian [CH/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). CULLY, Doris, F. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). PARESS, Philip, S. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). COHEN, Charles, J. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). BROCHU, Richard [CA/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (74) Common Representative: MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).		(81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: DNA MOLECULES ENCODING <i>CTENOCEPHALIDES FELIS</i> GLUTAMATE GATED CHLORIDE CHANNELS (57) Abstract <p>To date, L-glutamate-gated chloride (GluCl) channels have been observed only in invertebrate organisms. Modulators of this channel (either agonists or antagonists) will interfere with neurotransmission. For example, agents such as avermectins activate the GluCl, causing paralysis due to blocking of neurotransmitter release, resulting in death of the organism. Because GluCl channels are invertebrate specific, they are excellent targets for the discovery of novel insecticides, anthelmintics and parasiticides that will display a marked safety profile because of the lack of mechanism based toxicity in vertebrate organisms. The present specification discloses isolation of a cDNA clone from the cat flea <i>Ctenocephalides felis</i> (CfGluCl-1) that encodes a L-glutamate-gated chloride channel. Heterologous expression of CfGluCl-1 cRNA in <i>Xenopus</i> oocytes results in robust expression of a L-glutamate-gated chloride current and the channel is activated and potentiated by avermectins. The expression of CfGluCl-1 in a heterologous expression system is useful to screens for novel GluCl channel agonists and antagonists. Additionally, this specification discloses improved methods of screening for GluCl channel modulators.</p>		

AL

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

TITLE OF THE INVENTION

DNA MOLECULES ENCODING *CTENOCEPHALIDES FELIS*

5 GLUTAMATE GATED CHLORIDE CHANNELS

CROSS-REFERENCE TO RELATED APPLICATIONS

This is a continuation of provisional application number
60/055,451 filed August 11, 1997.

10

STATEMENT REGARDING FEDERALLY-SPONSORED R&D

Not applicable.

REFERENCE TO MICROFICHE APPENDIX

15

Not applicable.

FIELD OF THE INVENTION

The present invention relates in part to isolated nucleic acid
molecules (polynucleotides) which encode *Ctenocephalides felis* (flea)
20 glutamate gated chloride channels. The present invention also relates to
recombinant vectors and recombinant hosts which contain a DNA
fragment encoding *C. felis* glutamate gated chloride channels,
substantially purified forms of associated *C. felis* glutamate gated
chloride channels, associated mutant proteins, and methods associated
25 with identifying compounds which modulate associated *Ctenocephalides*
felis glutamate gated chloride channels, which will be useful as
insecticides.

BACKGROUND OF THE INVENTION

30

Glutamate-gated chloride channels, or H-receptors, have
been identified in arthropod nerve and muscle (Lingle et al, 1981, *Brain*
Res. 212: 481-488; Horseman et al., 1988, *Neurosci. Lett.* 85: 65-70;
Wafford and Sattelle, 1989, *J. Exp. Bio.* 144: 449-462; Lea and Usherwood,
1973, *Comp. Gen. Pharmacol.* 4: 333-350; and Cull-Candy, 1976, *J. Physiol.*
35 255: 449-464).

Additionally, glutamate-gated chloride channels have been cloned from the soil nematode *Caenorhabditis elegans* (Cully et al., 1994, *Nature* 371: 707-711; see also U.S. Patent No. 5,527,703) and *Drosophila melanogaster* (Cully et al., 1996, *J. Biol. Chem.* 271: 20187-20191).

Invertebrate glutamate-gated chloride channels are important targets for the widely used avermectin class of anthelmintic and insecticidal compounds. The avermectins are a family of macrocyclic lactones originally isolated from the actinomycete *Streptomyces avermitilis*. The semisynthetic avermectin derivative, ivermectin (22,23-dihydro-avermectin B_{1a}), is used throughout the world to treat parasitic helminths and insect pests of man and animals. The avermectins remain the most potent broad spectrum endectocides exhibiting low toxicity to the host. After many years of use in the field, there remains little resistance to avermectin in the insect population. The combination of good therapeutic index and low resistance strongly suggests that the glutamate-gated chloride (GluCl) channels remain good targets for insecticide development.

It would be advantageous to identify additional invertebrate genes encoding GluCl channels in order to allow screening to identify novel GluCl channel modulators that may have insecticidal, mitacidal and/or nematocidal activity for animal health or crop protection. The present invention addresses and meets these needs by disclosing isolated nucleic acid molecules which express a *Ctenocephalides felis* GluCl channel wherein expression of flea GluCl cRNA in *Xenopus* oocytes results in an active GluCl channel.

SUMMARY OF THE INVENTION

The present invention relates to isolated nucleic acid molecules (polynucleotides) which encode novel invertebrate GluCl channel proteins, especially nucleic acid molecules which encode a functional *C. felis* GluCl (herein, "CfGluCl") channel.

The present invention also relates to isolated nucleic acid fragments of CfGluCl which encode mRNA expressing a biologically active CfGluCl channel. Any such polynucleotide includes but is not necessarily limited to nucleotide substitutions, deletions, additions,

amino-terminal truncations and carboxy-terminal truncations such that these mutations encode cRNA which express a functional *C. felis* GluCl channel in a eukaryotic cell, such as *Xenopus* oocytes, so as to be useful for screening for agonists and/or antagonists of *C. felis* GluCl activity.

The isolated nucleic acid molecule of the present invention may include a deoxyribonucleic acid molecule (DNA), such as genomic DNA and complementary DNA (cDNA), which may be single (coding or noncoding strand) or double stranded, as well as synthetic DNA, such as a synthesized, single stranded polynucleotide. The isolated nucleic acid molecule of the present invention may also include a ribonucleic acid molecule (RNA), including but not limited to messenger RNA (mRNA) encoding a biologically active *C. felis* GluCl channel and complementary RNA (cRNA) transcribed from a recombinant expression vector comprising a DNA molecule which encodes a full-length or biologically active portion of the full-length *C. felis* GluCl channel.

A preferred aspect of the present invention is disclosed in Figures 1A-B and SEQ ID NO:1, an isolated cDNA molecule encoding a *C. felis* GluCl channel, CfGluCl-1.

The present invention relates to recombinant vectors and recombinant hosts, both prokaryotic and eukaryotic, which contain the substantially purified nucleic acid molecules disclosed throughout this specification, especially a nucleic acid molecule encoding a *C. felis* GluCl channel, CfGluCl, such as the cDNA molecule disclosed in Figures 1A-B and set forth in SEQ ID NO:1.

The present invention also relates to a substantially purified form of a *C. felis* GluCl channel protein and especially the *C. felis* GluCl channel disclosed in Figure 2 and set forth in SEQ ID NO:2.

The present invention relates to a substantially purified membrane preparation which comprises a *C. felis* GluCl channel and is essentially free from contaminating proteins, including but not limited to other *C. felis* source proteins or host proteins from a recombinant cell which expresses CfGluCl. Especially preferred is a membrane preparation which comprises *C. felis* GluCl channel disclosed in Figure 2 and set forth in SEQ ID NO:2. To this end, the present invention also relates to a substantially purified membrane preparation which is

purified from a recombinant host, whether a recombinant eukaryotic or recombinant prokaryotic host, wherein a recombinant vector expresses a *C. felis* GluCl channel. Especially preferred is a membrane preparation which comprises a recombinant form of the *C. felis* GluCl channel,
5 CfGluCl, disclosed in Figure 2 and set forth in SEQ ID NO:2, referred to as CfGluCl-1.

The present invention also relates to biologically active fragments and/or mutants of a *C. felis* GluCl channel protein, including but not limited to the CfGluCl protein disclosed in Figure 2 and set forth
10 in SEQ ID NO:2, including but not necessarily limited to amino acid substitutions, deletions, additions, amino terminal truncations and carboxy-terminal truncations such that these mutations provide for a biologically active channel which is useful in screening for agonists and/or antagonists of *C. felis* GluCl channel activity.

15 The present invention also relates to an isolated nucleic acid molecule (polynucleotide) which encodes a truncated form of the flea GluCl channel protein (herein, "tr-CfGluCl"), as exemplified in Figure 3 and set forth in SEQ ID NO:3. Co-expression of tr-CfGluCl in *Xenopus* oocytes with CfGluCl is shown to inhibit glutamate-gated channel
20 activity.

The present invention also relates to isolated nucleic acid fragments of tr-CfGluCl-1 (SEQ ID NO:3) which encodes cRNA expressing a biologically active form of tr-CfGluCl, including but not
25 limited to inhibition or promotion of CfGluCl channel activity in the target cell type. Any such polynucleotide includes but is not necessarily limited to nucleotide substitutions, deletions, additions, amino-terminal truncations and carboxy-terminal truncations from the truncated form.

Again, any such truncated nucleic acid molecule (as compared to CfGluCl) may include a deoxyribonucleic acid molecule
30 (DNA), such as genomic DNA and complementary DNA (cDNA), which may be single (coding or noncoding strand) or double stranded, as well as synthetic DNA, such as a synthesized, single stranded polynucleotide. The isolated nucleic acid molecule of the present invention may also include a ribonucleic acid molecule (RNA),
35 including but not limited to messenger RNA (mRNA) or complementary RNA (cRNA) transcribed from a recombinant expression vector

comprising a DNA molecule which encodes a truncated version of the full-length *C. felis* GluCl channel.

A preferred aspect of this portion of the invention is disclosed in Figures 3A-B and SEQ ID NO:4, an isolated cDNA molecule
5 encoding a truncated version of the *C. felis* GluCl channel.

The present invention also relates to recombinant vectors and recombinant hosts, both prokaryotic and eukaryotic, which contain the substantially purified nucleic acid molecules disclosed throughout this specification, especially a nucleic acid molecule encoding a
10 truncated version of a *C. felis* GluCl channel such as the cDNA molecule disclosed in Figures 3A-B and set forth in SEQ ID NO:3.

The present invention also relates to a substantially purified form of a truncated version of the *C. felis* GluCl channel, trCfGluCl, and especially the truncated version of the *C. felis* GluCl channel, which is
15 disclosed in Figure 4 and as set forth in SEQ ID NO:4, referred to as trCfGluCl-1.

The present invention also relates to biologically active fragments and/or mutants of the truncated *C. felis* GluCl channel, trCfGluCl-1, including but not necessarily limited to amino acid
20 substitutions, deletions, additions, amino terminal truncations and carboxy-terminal truncations.

It is an object of the present invention to provide an isolated nucleic acid molecule which encodes a novel form of a *C. felis* GluCl channel and biologically active fragments thereof which are derivatives
25 of SEQ ID NO:2.

It is a further object of the present invention to provide the *C. felis* GluCl channel proteins or protein fragments encoded by the nucleic acid molecules referred to in the preceding paragraph.

It is a further object of the present invention to provide
30 recombinant vectors and recombinant host cells which comprise a nucleic acid sequence encoding a *C. felis* GluCl channel or a biological equivalent thereof.

It is an object of the present invention to provide a substantially purified form of a *C. felis* GluCl channel or a biological
35 equivalent thereof, as set forth in SEQ ID NO:2.

It is also an object of the present invention to provide a membrane preparation membrane preparation which comprises a *C. felis* GluCl channel and is essentially free from contaminating proteins. This membrane preparation includes, but is not limited to, a membrane preparation purified from a recombinant host.

It is an object of the present invention to provide for biologically active fragments and/or mutants of CfGluCl, including but not necessarily limited to amino acid substitutions, deletions, additions, amino terminal truncations and carboxy-terminal truncations such that these mutations provide for proteins or protein fragments of diagnostic, therapeutic or prophylactic use.

It is an object of the present invention to provide a substantially purified form of CfGluCl-1, as set forth in SEQ ID NO:4.

It is an object of the present invention to provide for biologically active fragments and/or mutants of CfGluCl, including but not necessarily limited to amino acid substitutions, deletions, additions, amino terminal truncations and carboxy-terminal truncations.

As used herein, "GluCl" refers to a glutamate-gated chloride channel.

As used herein, "CfGluCl" refers to a biologically active form of a *C. felis* glutamate-gated chloride channel.

As used herein, "cDNA" refers to complementary DNA.

As used herein, "mRNA" refers to messenger RNA.

As used herein, "crRNA" refers to complementary RNA, transcribed from a recombinant cDNA template.

BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A-B shows the nucleotide sequence which comprises the open reading frame encoding the *C. felis* GluCl channel, CfGluCl-1.

Figure 2 shows the amino acid sequence of CfGluCl-1.

Figures 3A-B shows the nucleotide sequence which comprises the open reading frame encoding the truncated *C. felis* GluCl channel, trCfGluCl-1.

Figure 4 shows the amino acid sequence of trCfGluCl-1.

Figures 5A and 5B show activation of CfGluCl-1 by glutamate. Figure 5A shows superimposed current recordings in response to 10, 30, 100 and 300 μ M glutamate. Figure 5B shows the concentration-response curve for glutamate.

5 Figure 6 shows that the CfGluCl-1 channel is selective for chloride.

Figures 7A and 7B show that ivermectin phosphate (IVM- PO_4) is an agonist of the *C. felis* GluCl channel encoded by CfGluCl-1. Figure 7A shows superimposed current recordings showing activation
10 by 100 μ M glutamate and 10 nM IVM- PO_4 . Figure 7B shows the concentration-response curve for IVM- PO_4 for CfGluCl (0 mV), DmGluCl (0 mV) and DmGluCl (-80 mV).

DETAILED DESCRIPTION OF THE INVENTION

15 L-glutamate-gated chloride (GluCl) channels have been observed only in invertebrate organisms. A modulator of this channel (either an agonist or antagonist) will interfere with neurotransmission. Agents such as avermectins activate this channel and cause paralysis due to block of neurotransmitter release, resulting in
20 death of the organism. Because GluCl channels are invertebrate specific, they are excellent targets for the discovery of novel insecticides, anthelmintics and parasitocides that will display a marked safety profile because of the lack of mechanism based toxicity in vertebrate organisms. The present invention relates to isolated nucleic acid
25 molecules (polynucleotides) which encode novel invertebrate GluCl channel proteins, especially nucleic acid molecules which encode a functional *C. felis* GluCl channel (herein, "CfGluCl"). Heterologous expression of CfGluCl cRNA in *Xenopus* oocytes results in robust expression of a L-glutamate-gated chloride current. The CfGluCl
30 channel is activated and potentiated by avermectins (e.g., ivermectin phosphate). The expression of CfGluCl-1 in a heterologous expression system can be used to establish screens for novel GluCl channel modulators. Such compounds will be useful as antiparasitics and insecticides in human and animal health and crop protection, because
35 they will be devoid of mechanism based vertebrate toxicity.

To this end, the present invention also relates to isolated nucleic acid fragments of CfGluCl which encode cRNA expressing a biologically CfGluCl channel. Any such polynucleotide includes but is not necessarily limited to nucleotide substitutions, deletions, additions, amino-terminal truncations and carboxy-terminal truncations such that these mutations encode cRNA which express a functional *C. felis* GluCl channel in a eukaryotic cell, such as *Xenopus* oocytes, so as to be useful for screening for agonists and/or antagonists of *C. felis* GluCl activity.

A preferred aspect of the present invention is disclosed in Figures 1A-B and SEQ ID NO:1, an isolated cDNA molecule encoding a *C. felis* GluCl channel, CfGluCl-1.

The present invention also relates to recombinant vectors and recombinant hosts, both prokaryotic and eukaryotic, which contain the substantially purified nucleic acid molecules disclosed throughout this specification, especially a nucleic acid molecule encoding a *C. felis* GluCl channel, CfGluCl, such as the cDNA molecule disclosed in Figures 1A-B and set forth in SEQ ID NO:1.

The isolated nucleic acid molecule of the present invention may include a deoxyribonucleic acid molecule (DNA), such as genomic DNA and complementary DNA (cDNA), which may be single (coding or noncoding strand) or double stranded, as well as synthetic DNA, such as a synthesized, single stranded polynucleotide. The isolated nucleic acid molecule of the present invention may also include a ribonucleic acid molecule (RNA), including but not limited to messenger RNA (mRNA) encoding a biologically active *C. felis* GluCl channel and complementary RNA (cRNA) transcribed from a recombinant expression vector comprising a DNA molecule which encodes a full-length or biologically active portions of the full-length *C. felis* GluCl channel.

It is known that there is a substantial amount of redundancy in the various codons which code for specific amino acids. Therefore, this invention is also directed to those DNA sequences transcribing mRNA or cRNA comprising alternative codons which encode an identical amino acid, as shown below:

A=Ala=Alanine: codons GCA, GCC, GCG, GCU

C=Cys=Cysteine: codons UGC, UGU

- D=Asp=Aspartic acid: codons GAC, GAU
 E=Glu=Glutamic acid: codons GAA, GAG
 F=Phe=Phenylalanine: codons UUC, UUU
 G=Gly=Glycine: codons GGA, GGC, GGG, GGU
 5 H=His=Histidine: codons CAC, CAU
 I=Ile=Isoleucine: codons AUA, AUC, AUU
 K=Lys=Lysine: codons AAA, AAG
 L=Leu=Leucine: codons UUA, UUG, CUA, CUC, CUG, CUU
 M=Met=Methionine: codon AUG
 10 N=Asp=Asparagine: codons AAC, AAU
 P=Pro=Proline: codons CCA, CCC, CCG, CCU
 Q=Gln=Glutamine: codons CAA, CAG
 R=Arg=Arginine: codons AGA, AGG, CGA, CGC, CGG, CGU
 S=Ser=Serine: codons AGC, AGU, UCA, UCC, UCG, UCU
 15 T=Thr=Threonine: codons ACA, ACC, ACG, ACU
 V=Val=Valine: codons GUA, GUC, GUG, GUU
 W=Trp=Tryptophan: codon UGG
 Y=Tyr=Tyrosine: codons UAC, UAU

- Therefore, the present invention discloses codon
 20 redundancy which may result in differing DNA molecules expressing
 an identical protein. For purposes of this specification, a sequence
 bearing one or more replaced codons will be defined as a degenerate
 variation. Also included within the scope of this invention are
 mutations either in the DNA sequence or the translated protein which
 25 do not substantially alter the ultimate physical properties of the
 expressed protein. For example, substitution of valine for leucine,
 arginine for lysine, or asparagine for glutamine may not cause a change
 in functionality of the polypeptide.

- It is known that DNA sequences coding for a peptide may be
 30 altered so as to code for a peptide having properties that are different
 than those of the naturally occurring peptide. Methods of altering the
 DNA sequences include but are not limited to site-directed mutagenesis.
 Examples of altered properties include but are not limited to changes in
 the affinity of an enzyme for a substrate or a receptor for a ligand.

- 35 As used herein, "purified" and "isolated" are utilized
 interchangeably to stand for the proposition that the nucleic acid,

protein, or respective fragment thereof in question has been substantially removed from its *in vivo* environment so that it may be manipulated by the skilled artisan, such as but not limited to nucleotide sequencing, restriction digestion, site-directed mutagenesis, and subcloning into expression vectors for a nucleic acid fragment as well as obtaining the protein or protein fragment in pure quantities so as to afford the opportunity to generate polyclonal antibodies, monoclonal antibodies, amino acid sequencing, and peptide digestion. Therefore, the nucleic acids claimed herein may be present in whole cells or in cell lysates or in a partially purified or substantially purified form. A nucleic acid is considered substantially purified when it is purified away from environmental contaminants. Thus, a nucleic acid sequence isolated from cells is considered to be substantially purified when purified from cellular components by standard methods while a chemically synthesized nucleic acid sequence is considered to be substantially purified when purified from its chemical precursors.

The present invention also relates to a substantially purified form of a *C. felis* GluCl channel, CfGluCl, and especially the *C. felis* GluCl channel which is disclosed in Figure 2 and as set forth in SEQ ID NO:2, referred to as CfGluCl-1.

The present invention also relates to a substantially purified membrane preparation which comprises a *C. felis* GluCl channel and is essentially free from contaminating proteins. Especially preferred is a membrane preparation which comprises a *C. felis* GluCl channel disclosed in Figure 2 and set forth in SEQ ID NO:2, referred to as CfGluCl-1.

The present invention also relates to a substantially purified membrane preparation which is purified from a recombinant host, whether a recombinant eukaryotic or recombinant prokaryotic host, wherein a recombinant vector expresses a *C. felis* GluCl channel. Especially preferred is a membrane preparation which comprises a recombinant form of the *C. felis* GluCl channel, CfGluCl, disclosed in Figure 2 and set forth in SEQ ID NO:2, referred to as CfGluCl-1.

The present invention also relates to biologically active fragments and/or mutants of CfGluCl-1, including but not necessarily limited to amino acid substitutions, deletions, additions, amino terminal

truncations and carboxy-terminal truncations such that these mutations provide for a biologically active channel which is useful in screening for agonists and/or antagonists of *C. felis* GluCl channel activity.

5 As used herein, a "biologically active equivalent" or "functional derivative" of a wild-type *C. felis* GluCl channel possesses a biological activity that is substantially similar to the biological activity of the wild type *C. felis* GluCl channel. The term "functional derivative" is intended to include the "fragments," "mutants," "variants," "degenerate
10 variants," "analogs" and "homologues" or to "chemical derivatives" of the wild type *C. felis* GluCl channel protein. The term "fragment" is meant to refer to any polypeptide subset of a wild-type *C. felis* GluCl channel. The term "mutant" is meant to refer to a molecule that may be substantially similar to the wild-type form but possesses distinguishing
15 biological characteristics. Such altered characteristics include but are in no way limited to altered substrate binding, altered substrate affinity and altered sensitivity to chemical compounds affecting biological activity of the *C. felis* GluCl channel and/or *C. felis* GluCl channel derivative. The term "variant" is meant to refer to a molecule
20 substantially similar in structure and function to either the entire wild-type protein or to a fragment thereof. A molecule is "substantially similar" to a wild-type *C. felis* GluCl channel and/or *C. felis* GluCl channel-like protein if both molecules have substantially similar structures or if both molecules possess similar biological activity. Therefore, if the two molecules possess substantially similar activity,
25 they are considered to be variants even if the structure of one of the molecules is not found in the other or even if the two amino acid sequences are not identical. The term "analog" refers to a molecule substantially similar in function to either the full-length *C. felis* GluCl
30 channel and/or *C. felis* GluCl channel or to a biologically active fragment thereof.

 The present invention also relates to isolated an isolated nucleic acid molecule (polynucleotide) which encodes a truncated form of the flea GluCl channel protein (herein, "tr-CfGluCl"), as exemplified
35 in Figures 3A-B and SEQ ID NO:3. Co-expression of tr-CfGluCl in *Xenopus* oocytes with CfGluCl inhibits glutamate-gated channel activity.

The present invention also relates to isolated nucleic acid fragments of SEQ ID NO:3 which encode cRNA expressing a biologically active form of tr-CfGluCl, including but not limited to inhibition or promotion of CfGluCl channel activity in the target cell type. Any such polynucleotide includes but is not necessarily limited to nucleotide
5 substitutions, deletions, additions, amino-terminal truncations and carboxy-terminal truncations from the truncated form.

Again, any such truncated nucleic acid molecule (as compared to CfGluCl) may include a deoxyribonucleic acid molecule (DNA), such as genomic DNA and complementary DNA (cDNA), which
10 may be single (coding or noncoding strand) or double stranded, as well as synthetic DNA, such as a synthesized, single stranded polynucleotide. The isolated nucleic acid molecule of the present invention may also include a ribonucleic acid molecule (RNA),
15 including but not limited to messenger RNA (mRNA) or complementary RNA (cRNA) transcribed from a recombinant expression vector comprising a DNA molecule which encodes a truncated version of the full-length *C. felis* GluCl channel.

The present invention also relates to recombinant vectors and recombinant hosts, both prokaryotic and eukaryotic, which contain
20 the substantially purified nucleic acid molecules disclosed throughout this specification, especially a nucleic acid molecule encoding a truncated version of a *C. felis* GluCl channel, CfGluCl., such as the cDNA molecule disclosed in Figures 3A-B and set forth in SEQ ID NO:3.

The present invention also relates to a substantially purified form of a truncated version of the *C. felis* GluCl channel, trCfGluCl, and especially the truncated version of the *C. felis* GluCl channel, which is
25 disclosed in Figure 4 and as set forth in SEQ ID NO:4, referred to as trCfGluCl-1.

The present invention also relates to biologically active fragments and/or mutants of trCfGluCl-1, including but not necessarily
30 limited to amino acid substitutions, deletions, additions, amino terminal truncations and carboxy-terminal truncations.

Any of a variety of procedures may be used to clone a *C. felis* GluCl channel. These methods include, but are not limited to, (1) a
35 RACE PCR cloning technique (Frohman, et al., 1988, *Proc. Natl. Acad.*

Sci. USA 85: 8998-9002). 5' and/or 3' RACE may be performed to generate a full-length cDNA sequence. This strategy involves using gene-specific oligonucleotide primers for PCR amplification of *C. felis* GluCl channel cDNA. These gene-specific primers are designed through identification of an expressed sequence tag (EST) nucleotide sequence which has been identified by searching any number of publicly available nucleic acid and protein databases; (2) direct functional expression of the *C. felis* GluCl channel cDNA following the construction of a *C. felis* GluCl channel-containing cDNA library in an appropriate expression vector system; (3) screening a *C. felis* GluCl channel-containing cDNA library constructed in a bacteriophage or plasmid shuttle vector with a labeled degenerate oligonucleotide probe designed from the amino acid sequence of the *C. felis* GluCl channel protein; and (4) screening a *C. felis* GluCl channel-containing cDNA library constructed in a bacteriophage or plasmid shuttle vector with a partial cDNA encoding the *C. felis* GluCl channel protein. This partial cDNA is obtained by the specific PCR amplification of *C. felis* GluCl channel DNA fragments through the design of degenerate oligonucleotide primers from the amino acid sequence known for other kinases which are related to the *C. felis* GluCl channel protein; (5) screening a *C. felis* GluCl channel-containing cDNA library constructed in a bacteriophage or plasmid shuttle vector with a partial cDNA encoding the *C. felis* GluCl channel protein. This strategy may also involve using gene-specific oligonucleotide primers for PCR amplification of *C. felis* GluCl channel cDNA identified as an EST as described above; or (6) designing 5' and 3' gene specific oligonucleotides using SEQ ID NO: 1 as a template so that either the full-length cDNA may be generated by known RACE techniques, or a portion of the coding region may be generated by these same known RACE techniques to generate and isolate a portion of the coding region to use as a probe to screen one of numerous types of cDNA and/or genomic libraries in order to isolate a full-length version of the nucleotide sequence encoding *C. felis* GluCl channel.

It is readily apparent to those skilled in the art that suitable cDNA libraries may be prepared from cells or cell lines which have *C. felis* GluCl channel activity. The selection of cells or cell lines for use in preparing a cDNA library to isolate a cDNA encoding *C. felis* GluCl

channel may be done by first measuring cell-associated *C. felis* GluCl channel activity using any known assay available for such a purpose.

Preparation of cDNA libraries can be performed by standard techniques well known in the art. Well known cDNA library construction techniques can be found for example, in Sambrook et al., 5 1989, *Molecular Cloning: A Laboratory Manual*; Cold Spring Harbor Laboratory, Cold Spring Harbor, New York. Complementary DNA libraries may also be obtained from numerous commercial sources, including but not limited to Clontech Laboratories, Inc. and Stratagene.

10 It is also readily apparent to those skilled in the art that DNA encoding *C. felis* GluCl channel may also be isolated from a suitable genomic DNA library. Construction of genomic DNA libraries can be performed by standard techniques well known in the art. Well known genomic DNA library construction techniques can be found in 15 Sambrook, et al., *supra*.

In order to clone the *C. felis* GluCl channel gene by one of the preferred methods, the amino acid sequence or DNA sequence of *C. felis* GluCl channel or a homologous protein may be necessary. To accomplish this, the *C. felis* GluCl channel protein or a homologous 20 protein may be purified and partial amino acid sequence determined by automated sequenators. It is not necessary to determine the entire amino acid sequence, but the linear sequence of two regions of 6 to 8 amino acids can be determined for the PCR amplification of a partial *C. felis* GluCl channel DNA fragment. Once suitable amino acid 25 sequences have been identified, the DNA sequences capable of encoding them are synthesized. Because the genetic code is degenerate, more than one codon may be used to encode a particular amino acid, and therefore, the amino acid sequence can be encoded by any of a set of similar DNA oligonucleotides. Only one member of the set will be 30 identical to the *C. felis* GluCl channel sequence but others in the set will be capable of hybridizing to *C. felis* GluCl channel DNA even in the presence of DNA oligonucleotides with mismatches. The mismatched DNA oligonucleotides may still sufficiently hybridize to the *C. felis* GluCl channel DNA to permit identification and isolation of *C. felis* GluCl 35 channel encoding DNA. Alternatively, the nucleotide sequence of a region of an expressed sequence may be identified by searching one or

more available genomic databases. Gene-specific primers may be used to perform PCR amplification of a cDNA of interest from either a cDNA library or a population of cDNAs. As noted above, the appropriate nucleotide sequence for use in a PCR-based method may be obtained
5 from SEQ ID NO: 1, either for the purpose of isolating overlapping 5' and 3' RACE products for generation of a full-length sequence coding for *C. felis* GluCl channel, or to isolate a portion of the nucleotide sequence coding for *C. felis* GluCl channel for use as a probe to screen one or more cDNA- or genomic-based libraries to isolate a full-length sequence
10 encoding *C. felis* GluCl channel or *C. felis* GluCl channel-like proteins.

In an exemplified method, a *C. felis* GluCl channel cDNA was generated by screening a *C. felis* cDNA library prepared in the phagemid cloning vector λZAPII (Stratagene, LaJolla, CA) This library was screened with a DNA probe corresponding to nucleotides 471 to 1760
15 of the *DrosGluCl* cDNA (Cully et al., 1996, *J. Biol. Chem.* 271: 20187-20191; accession number U58776) which codes for all but the last four amino acids of the *Drosophila* glutamate-gated chloride channel. Two positive clones, F5A and F6 were chosen for further analysis. These cDNA clones were shown to encode a truncated polypeptide disclosed in
20 Figure 4 and SEQ ID NO:4, referred to within this specification as trCfGluCl-1. It is shown in this specification that the truncation at the amino-terminal region of clone F5A produced a frame shift mutation. It is also shown in this specification that this truncation was in fact due to a deletion of 71 nucleotides at the presumptive amino-terminal
25 extracellular domain, resulting in a frame shift mutation that resulted in expression of the truncated protein, trCfGluCl-1. A cDNA fragment containing the missing portion of a putative *C. felis* GluCl channel cDNA was generated by PCR amplification of randomly primed flea cDNA. Primer-1 (5'-CTCAGAGTCAGGATCCGGCTA-3';
30 SEQ ID NO:5) and Primer-2 (5'-CTGAAAGTTAACTGGACACTG-3'; SEQ ID NO:6) were used in a standard PCR reaction to amplify a 532 bp PCR fragment that was shown by DNA sequence analysis to contain the missing 71 nucleotides and flanking sequences disclosed in the F5A clone. A 517 bp BamHI/HpaI fragment of this PCR product was isolated
35 and inserted into a BamHI/HpaI digested F5A clone to generate the full length cDNA clone designated Flea51, as shown in Figures 1A-B. This

cDNA molecule contains an open reading frame which encodes a *C. felis* GluCl channel, as shown in Figure 2, as set forth as SEQ ID NO:2. In addition, the 5' untranslated region the exemplified cDNA which encodes a CfGluCl channel protein was determined and is presented as
5 SEQ ID NO:7.

A variety of mammalian expression vectors may be used to express a recombinant *C. felis* GluCl channel protein in mammalian cells. Expression vectors are defined herein as DNA sequences that are required for the transcription of cloned DNA and the translation of their
10 mRNAs in an appropriate host. Such vectors can be used to express eukaryotic DNA in a variety of hosts such as bacteria, blue green algae, plant cells, insect cells and animal cells. Specifically designed vectors allow the shuttling of DNA between hosts such as bacteria-yeast or bacteria-animal cells. An appropriately constructed expression vector
15 should contain: an origin of replication for autonomous replication in host cells, selectable markers, a limited number of useful restriction enzyme sites, a potential for high copy number, and active promoters. A promoter is defined as a DNA sequence that directs RNA polymerase to bind to DNA and initiate RNA synthesis. A strong promoter is one
20 which causes mRNAs to be initiated at high frequency. Expression vectors may include, but are not limited to, cloning vectors, modified cloning vectors, specifically designed plasmids or viruses.

Commercially available mammalian expression vectors which may be suitable for recombinant *C. felis* GluCl channel protein
25 expression, include but are not limited to, pcDNA3.1 (Invitrogen), pLITMUS28, pLITMUS29, pLITMUS38 and pLITMUS39 (New England Biolabs), pcDNA1, pcDNA1amp (Invitrogen), pcDNA3 (Invitrogen), pMC1neo (Stratagene), pXT1 (Stratagene), pSG5 (Stratagene), EBO-pSV2-neo (ATCC 37593) pBPV-1(8-2) (ATCC 37110), pdBPV-MMTneo(342-12) (ATCC 37224), pRSVgpt (ATCC 37199), pRSVneo (ATCC 37198), pSV2-dhfr (ATCC 37146), pUCtag (ATCC 37460), and λ ZD35 (ATCC 37565).
30

A variety of bacterial expression vectors may be used to express a recombinant *C. felis* GluCl channel protein in bacterial cells. Commercially available bacterial expression vectors which may be
35 suitable for recombinant *C. felis* GluCl channel protein expression

include, but are not limited to pCR2.1 (Invitrogen), pET11a (Novagen), lambda gt11 (Invitrogen), and pKK223-3 (Pharmacia).

A variety of fungal cell expression vectors may be used to express recombinant *C. felis* GluCl channel protein in fungal cells.

- 5 Commercially available fungal cell expression vectors which may be suitable for recombinant *C. felis* GluCl channel expression include but are not limited to pYES2 (Invitrogen) and *Pichia* expression vector (Invitrogen).

- 10 A variety of insect cell expression vectors may be used to express recombinant receptor in insect cells. Commercially available insect cell expression vectors which may be suitable for recombinant expression of a *C. felis* GluCl channel protein include but are not limited to pBlueBacIII and pBlueBacHis2 (Invitrogen), and pAcG2T (Pharmingen).

- 15 An expression vector containing DNA encoding a *C. felis* GluCl channel protein and/or *C. felis* GluCl channel-like protein may be used for expression of *C. felis* GluCl channel protein in a recombinant host cell. Recombinant host cells may be prokaryotic or eukaryotic, including but not limited to bacteria such as *E. coli*, fungal cells such as yeast, mammalian cells including but not limited to cell lines of human, 20 bovine, porcine, monkey and rodent origin, and insect cells including but not limited to *Drosophila*- and silkworm-derived cell lines. Cell lines derived from mammalian species which may be suitable and which are commercially available, include but are not limited to, L cells L-M(TK⁻) 25 (ATCC CCL 1.3), L cells L-M (ATCC CCL 1.2), Saos-2 (ATCC HTB-85), 293 (ATCC CRL 1573), Raji (ATCC CCL 86), CV-1 (ATCC CCL 70), COS-1 (ATCC CRL 1650), COS-7 (ATCC CRL 1651), CHO-K1 (ATCC CCL 61), 3T3 (ATCC CCL 92), NIH/3T3 (ATCC CRL 1658), HeLa (ATCC CCL 2), C127I (ATCC CRL 1616), BS-C-1 (ATCC CCL 26), MRC-5 (ATCC CCL 30 171) and CPAE (ATCC CCL 209).

- The cloned human *C. felis* GluCl channel cDNA obtained through the methods described above may be recombinantly expressed by molecular cloning into an expression vector (such as pcDNA3.1, pCR2.1, pBlueBacHis2 and pLITMUS28) containing a suitable promoter and 35 other appropriate transcription regulatory elements, and transferred into prokaryotic or eukaryotic host cells to produce recombinant *C. felis*

GluCl channel protein. Techniques for such manipulations can be found described in Sambrook, et al., *supra*, are discussed at length in the Example section and are well known and easily available to the artisan of ordinary skill in the art.

5 The expression vector may be introduced into host cells via any one of a number of techniques including but not limited to direct injection, transformation, transfection, protoplast fusion, lipofection, and electroporation. The expression vector-containing cells are clonally propagated and individually analyzed to determine whether they
10 produce *C. felis* GluCl protein. Identification of *C. felis* GluCl expressing host cell clones may be done by several means, including but not limited to immunological reactivity with anti-*C. felis* GluCl antibodies, and the presence of host cell-associated GluCl activity.

 Expression of *C. felis* GluCl DNA may also be performed
15 using *in vitro* produced synthetic mRNA. Synthetic mRNA can be efficiently translated in various cell-free systems, including but not limited to wheat germ extracts and reticulocyte extracts, as well as efficiently translated in cell based systems, including but not limited to microinjection into frog oocytes, with microinjection into frog oocytes
20 being preferred.

 To determine the *C. felis* GluCl channel cDNA sequence(s) that yields optimal levels of *C. felis* GluCl channel protein, cDNA molecules including but not limited to the following can be constructed: a cDNA fragment containing the full-length open reading frame for *C.*
25 *felis* GluCl channel protein as well as various constructs containing portions of the cDNA encoding only specific domains of the protein or rearranged domains of the protein. All constructs can be designed to contain none, all or portions of the 5' and/or 3' untranslated region of a *C. felis* GluCl channel cDNA. The expression levels and activity of *C.*
30 *felis* GluCl channel protein can be determined following the introduction, both singly and in combination, of these constructs into appropriate host cells. Following determination of the *C. felis* GluCl channel cDNA cassette yielding optimal expression in transient assays, this *C. felis* GluCl channel cDNA construct is transferred to a variety of
35 expression vectors (including recombinant viruses), including but not limited to those for expression in host cells including, but not limited to,

mammalian cells, insect cells such as baculovirus-infected insect cells, oocytes such as *Xenopus* oocytes, bacterial such as *E. coli*, and the yeast *S. cerevisiae*.

5 The present invention also relates to methods of expressing an active *C. felis* GluCl channel protein and biological equivalents disclosed herein, assays employing these recombinantly expressed gene products, cells expressing these gene products, and agonistic and/or antagonistic compounds identified through the use of assays utilizing these recombinant forms, including, but not limited to, one or more
10 modulators of a *C. felis* GluCl channel.

A preferred expression system for the electrophysiological-based assays and related improved methods of measuring glutamate-gated chloride channel activity and modulation comprise injecting nucleic acid molecules into *Xenopus laevis* oocytes. The general use of
15 *Xenopus* oocytes in the study of ion channel activity is known in the art (Dascal, 1987, *Crit. Rev. Biochem.* 22: 317-317; Lester, 1988, *Science* 241: 1057-1063; see also *Methods of Enzymology*, Vol. 207, 1992, Ch. 14-25, Rudy and Iverson, ed., Academic Press, Inc., New York). A portion of the present invention discloses an improved method of measuring
20 channel activity and modulation by agonists and/or antagonists which is several-fold more sensitive than previously disclosed. The *Xenopus* oocytes are injected with nucleic acid material, including but not limited to DNA, mRNA or cRNA which encode a gated-channel, wherein channel activity may be measured as well as response of the channel to
25 various modulators. To this end, the present invention relates to an improved *in vitro* method of measuring ion channel activity in eukaryotic cells, especially *Xenopus* oocytes, which comprises utilizing a holding potential more positive than the reversal potential for chloride (i.e., greater than -30 mV), preferably about 0 mV. This alteration in
30 assay measurement conditions has resulting in a 10-fold increase in sensitivity of the assay to modulation by ivermectin phosphate. Therefore, this improved assay will allow screening and selecting for compounds which modulate GluCl activity at levels which were previously thought to be undetectable. Data is presented in Example
35 Section 2 which exemplifies the use of this improved assay for detecting expressed ion channel activity in *Xenopus* oocytes. It will be evident to

the skilled artisan that this improved method may be utilized in various ion channel measurement assays, and especially assays which measure glutamate-gated activity in a eukaryotic cell, such as a *Xenopus* oocyte. It is especially preferred that invertebrate glutamate-gated chloride channels, including but in not way limited to *Caenorhabditis elegans*, *Drosophila melanogaster* and *Ctenocephalides felis* glutamate-gated channel proteins, be utilized in an assay to screen and select for compounds which modulate the activity of these channels.

Levels of *C. felis* GluCl protein in host cells are quantitated by immunoaffinity and/or ligand affinity techniques. Cells expressing GluCl can be assayed for the number of GluCl molecules expressed by measuring the amount of radioactive glutamate or ivermectin binding to cell membranes. GluCl-specific affinity beads or GluCl-specific antibodies are used to isolate for example ³⁵S-methionine labelled or unlabelled GluCl protein. Labelled GluCl protein is analyzed by SDS-PAGE. Unlabelled GluCl protein is detected by Western blotting, ELISA or RIA assays employing GluCl specific antibodies.

Recombinant *C. felis* GluCl channel protein can be separated from other cellular proteins by use of an immunoaffinity column made with monoclonal or polyclonal antibodies specific for full-length *C. felis* GluCl channel protein, or polypeptide fragments of *C. felis* GluCl channel protein. Additionally, polyclonal or monoclonal antibodies may be raised against a synthetic peptide (usually from about 9 to about 25 amino acids in length) from a portion of the protein as disclosed in SEQ ID NO:2. Monospecific antibodies to *C. felis* GluCl channel are purified from mammalian antisera containing antibodies reactive against a *C. felis* GluCl channel or are prepared as monoclonal antibodies reactive with a *C. felis* GluCl channel using the technique of Kohler and Milstein (1975, *Nature* 256: 495-497). Monospecific antibody as used herein is defined as a single antibody species or multiple antibody species with homogenous binding characteristics for a *C. felis* GluCl channel. Homogenous binding as used herein refers to the ability of the antibody species to bind to a specific antigen or epitope, such as those associated with a *C. felis* GluCl channel, as described above. *C. felis* GluCl channel protein-specific antibodies are raised by immunizing animals such as mice, rats, guinea pigs, rabbits, goats,

horses and the like, with an appropriate concentration of *C. felis* GluCl channel protein or a synthetic peptide generated from a portion of *C. felis* GluCl channel with or without an immune adjuvant. Therefore, the present invention also relates to polyclonal and monoclonal antibodies raised in response to the *C. felis* GluCl channel protein disclosed herein, or a biologically active fragment thereof.

Preimmune serum is collected prior to the first immunization. Each animal receives between about 0.1 μ g and about 1000 μ g of *C. felis* GluCl channel protein associated with an acceptable immune adjuvant. Such acceptable adjuvants include, but are not limited to, Freund's complete, Freund's incomplete, alum-precipitate, water in oil emulsion containing *Corynebacterium parvum* and tRNA. The initial immunization consists of *C. felis* GluCl channel protein or peptide fragment thereof in, preferably, Freund's complete adjuvant at multiple sites either subcutaneously (SC), intraperitoneally (IP) or both. Each animal is bled at regular intervals, preferably weekly, to determine antibody titer. The animals may or may not receive booster injections following the initial immunization. Those animals receiving booster injections are generally given an equal amount of *C. felis* GluCl channel in Freund's incomplete adjuvant by the same route. Booster injections are given at about three week intervals until maximal titers are obtained. At about 7 days after each booster immunization or about weekly after a single immunization, the animals are bled, the serum collected, and aliquots are stored at about -20°C.

Monoclonal antibodies (mAb) reactive with *C. felis* GluCl channel are prepared by immunizing inbred mice, preferably Balb/c, with *C. felis* GluCl channel protein. The mice are immunized by the IP or SC route with about 1 μ g to about 100 μ g, preferably about 10 μ g, of *C. felis* GluCl channel protein in about 0.5 ml buffer or saline incorporated in an equal volume of an acceptable adjuvant, as discussed above. Freund's complete adjuvant is preferred. The mice receive an initial immunization on day 0 and are rested for about 3 to about 30 weeks. Immunized mice are given one or more booster immunizations of about 1 to about 100 μ g of *C. felis* GluCl channel protein in a buffer solution such as phosphate buffered saline by the intravenous (IV) route. Lymphocytes, from antibody positive mice, preferably splenic

lymphocytes, are obtained by removing spleens from immunized mice by standard procedures known in the art. Hybridoma cells are produced by mixing the splenic lymphocytes with an appropriate fusion partner, preferably myeloma cells, under conditions which will allow the
5 formation of stable hybridomas. Fusion partners may include, but are not limited to: mouse myelomas P3/NS1/Ag 4-1; MPC-11; S-194 and Sp 2/0, with Sp 2/0 being preferred. The antibody producing cells and myeloma cells are fused in polyethylene glycol, about 1000 mol. wt., at concentrations from about 30% to about 50%. Fused hybridoma cells are
10 selected by growth in hypoxanthine, thymidine and aminopterin supplemented Dulbecco's Modified Eagles Medium (DMEM) by procedures known in the art. Supernatant fluids are collected from growth positive wells on about days 14, 18, and 21 and are screened for antibody production by an immunoassay such as solid phase
15 immunoradioassay (SPIRA) using *C. felis* GluCl channel protein as the antigen. The culture fluids are also tested in the Ouchterlony precipitation assay to determine the isotype of the mAb. Hybridoma cells from antibody positive wells are cloned by a technique such as the soft agar technique of MacPherson, 1973, Soft Agar Techniques, in *Tissue*
20 *Culture Methods and Applications*, Kruse and Paterson, Eds., Academic Press.

Monoclonal antibodies are produced *in vivo* by injection of pristine primed Balb/c mice, approximately 0.5 ml per mouse, with about 2×10^6 to about 6×10^6 hybridoma cells about 4 days after priming.
25 Ascites fluid is collected at approximately 8-12 days after cell transfer and the monoclonal antibodies are purified by techniques known in the art.

In vitro production of anti-*C. felis* GluCl channel protein mAb is carried out by growing the hybridoma in DMEM containing
30 about 2% fetal calf serum to obtain sufficient quantities of the specific mAb. The mAb are purified by techniques known in the art.

Antibody titers of ascites or hybridoma culture fluids are determined by various serological or immunological assays which include, but are not limited to, precipitation, passive agglutination,
35 enzyme-linked immunosorbent antibody (ELISA) technique and radioimmunoassay (RIA) techniques. Similar assays are used to detect

the presence of *C. felis* GluCl channel protein in body fluids or tissue and cell extracts.

It is readily apparent to those skilled in the art that the above described methods for producing monospecific antibodies may be
5 utilized to produce antibodies specific for *C. felis* GluCl channel peptide fragments, or full-length *C. felis* GluCl channel protein.

C. felis GluCl channel antibody affinity columns are made, for example, by adding the antibodies to Affigel-10 (Biorad), a gel support which is pre-activated with N-hydroxysuccinimide esters such that the
10 antibodies form covalent linkages with the agarose gel bead support. The antibodies are then coupled to the gel via amide bonds with the spacer arm. The remaining activated esters are then quenched with 1M ethanolamine HCl (pH 8). The column is washed with water followed by 0.23 M glycine HCl (pH 2.6) to remove any non-conjugated antibody or
15 extraneous protein. The column is then equilibrated in phosphate buffered saline (pH 7.3) and the cell culture supernatants or cell extracts containing full-length *C. felis* GluCl channel protein or *C. felis* GluCl channel protein fragments are slowly passed through the column. The column is then washed with phosphate buffered saline until the optical
20 density (A_{280}) falls to background, then the protein is eluted with 0.23 M glycine-HCl (pH 2.6). The purified *C. felis* GluCl channel protein is then dialyzed against phosphate buffered saline.

Levels of *C. felis* GluCl channel protein in host cells is quantified by a variety of techniques including, but not limited to,
25 immunoaffinity and/or ligand affinity techniques. *C. felis* GluCl channel protein-specific affinity beads or *C. felis* GluCl channel protein - specific antibodies are used to isolate ^{35}S -methionine labeled or unlabelled *C. felis* GluCl channel protein. Labeled *C. felis* GluCl channel protein is analyzed by SDS-PAGE. Unlabelled *C. felis* GluCl
30 channel protein is detected by Western blotting, ELISA or RIA assays employing *C. felis* GluCl channel protein specific antibodies.

Following expression of *C. felis* GluCl channel protein in a host cell, *C. felis* GluCl channel protein may be recovered to provide *C. felis* GluCl channel protein in active form. Several *C. felis* GluCl
35 channel protein purification procedures are available and suitable for use. Recombinant *C. felis* GluCl channel protein may be purified from

cell lysates and extracts, or from conditioned culture medium, by various combinations of, or individual application of salt fractionation, ion exchange chromatography, size exclusion chromatography, hydroxylapatite adsorption chromatography and hydrophobic interaction chromatography. It is also possible to prepare membrane preparations from a recombinant host cell which contains a recombinant vector which expresses an active *C. felis* GluCl channel. Such membrane preparations from recombinant cells will be useful for *in vitro*-based screening assays for compounds which modulate *C. felis* GluCl channel activity.

Compounds identified according to the methods disclosed herein may be used alone at appropriate dosages defined by routine testing in order to obtain optimal inhibition of the GluCl receptor or its activity while minimizing any potential toxicity. In addition, co-administration or sequential administration of other agents may be desirable.

The method of the present invention also has the objective of providing suitable topical, oral, systemic and parenteral pharmaceutical formulations for use in the novel methods of treatment of the present invention. The compositions containing compounds identified according to this invention as the active ingredient for use in the modulation of GluCl receptors can be administered in a wide variety of therapeutic dosage forms in conventional vehicles for administration. For example, the compounds can be administered in such oral dosage forms as tablets, capsules (each including timed release and sustained release formulations), pills, powders, granules, elixirs, tinctures, solutions, suspensions, syrups and emulsions, or by injection. Likewise, they may also be administered in intravenous (both bolus and infusion), intraperitoneal, subcutaneous, topical with or without occlusion, or intramuscular form, all using forms well known to those of ordinary skill in the pharmaceutical arts. An effective but non-toxic amount of the compound desired can be employed as a GluCl modulating agent.

The daily dosage of the products may be varied over a wide range from 0.001 to 1,000 mg per patient, per day. For oral administration, the compositions are preferably provided in the form of scored or unscored tablets containing 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0,

15.0, 25.0, and 50.0 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated. An effective amount of the drug is ordinarily supplied at a dosage level of from about 0.0001 mg/kg to about 100 mg/kg of body weight per day. The dosages of the GluCl receptor modulators are adjusted when combined to achieve desired effects. On the other hand, dosages of these various agents may be independently optimized and combined to achieve a synergistic result wherein the pathology is reduced more than it would be if either agent were used alone.

Advantageously, compounds active in the method of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily. Furthermore, compounds active in the method of the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.

For combination treatment with more than one active agent, where the active agents are in separate dosage formulations, the active agents can be administered concurrently, or they each can be administered at separately staggered times.

The dosage regimen utilizing the compounds active in the method of the present invention is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound thereof employed. A physician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition. Optimal precision in achieving concentrations of drug within the range that yields efficacy without toxicity requires a regimen based on the kinetics of the drug's availability to target sites. This involves a consideration of the distribution, equilibrium, and elimination of a drug.

MISSING AT THE TIME OF PUBLICATION

MISSING AT THE TIME OF PUBLICATION

MISSING AT THE TIME OF PUBLICATION

The compounds active in the method disclosed herein are also useful against endo and ecto parasites which cause parasitic diseases in humans. Examples of such endoparasites which infect man include gastro-intestinal parasites of the genera *Ancylostoma*, *Necator*,
5 *Ascaris*, *Strongyloides*, *Trichinella*, *Capillaria*, *Trichuris*, *Enterobius*, and the like. Other endoparasites which infect man are found in the blood or in other organs. Examples of such parasites are the filarial worms *Wucheria*, *Brugia*, *Onchocerca*, and the like as well as extra-intestinal stages of the intestinal worms *Strongylides* and *Trichinella*.
10 Ectoparasites which parasitize man include arthropods such as ticks, fleas, mites, lice, and the like and, as with domestic animals, infections by these parasites can result in transmission of serious and even fatal diseases. The active compounds are active against these endo and ecto parasites and in addition are also active against biting insects and other
15 dipterous pests which annoy humans.

The compounds active in the method disclosed herein are also useful against common household pests such as *Blatella sp.* (cockroach), *Tineola sp.* (clothes moth), *Attagenus sp.* (carpet beetle), *Musca domestica* (housefly) and against *Solenopsis Invicta* (imported
20 fire ant).

The compounds active in the method disclosed herein are furthermore useful against agricultural pests such as aphids (*Acyrtosiphon sp.*), locusts, spider mites, and boll weevils as well as against insect pests which attack stored grains such as *Tribolium sp.*
25 and *Tenebrio sp.*, and against immature stages of insects living on plant tissue. The compounds are also useful as a nematocide for the control of soil nematodes and plant parasites such as *Meloidogyne sp.*, which may be agriculturally important.

For use as an antiparasitic agent in animals the
30 compounds may be administered internally either orally, or by injection, or topically as a liquid drench or as a shampoo.

For oral administration, the compounds active in the method disclosed herein may be administered in capsule, tablet, or bolus form or alternatively they can be mixed in the animals feed. The
35 capsules, tablets, and boluses are comprised of the active ingredient in combination with an appropriate carrier vehicle such as starch, talc,

magnesium stearate, or di-calcium phosphate. These unit dosage forms are prepared by intimately mixing the active ingredient with suitable finely-powdered inert ingredients including diluents, fillers, disintegrating agents, and/or binders such that a uniform mixture is obtained. An inert ingredient is one that will not react with the compounds and which is non-toxic to the animal being treated. Suitable inert ingredients include starch, lactose, talc, magnesium stearate, vegetable gums and oils, and the like. These formulations may contain a widely variable amount of the active and inactive ingredients depending on numerous factors such as the size and type of the animal species to be treated and the type and severity of the infection. The active ingredient may also be administered as an additive to the feed by simply mixing the compound with the feedstuff or by applying the compound to the surface of the feed. Alternatively the active ingredient may be mixed with an inert carrier and the resulting composition may then either be mixed with the feed or fed directly to the animal. Suitable inert carriers include corn meal, citrus meal, fermentation residues, soya grits, dried grains and the like. The active ingredients are intimately mixed with these inert carriers by grinding, stirring, milling, or tumbling such that the final composition contains from 0.001 to 5% by weight of the active ingredient.

The compounds active in the method disclosed herein may alternatively be administered parenterally via injection of a formulation consisting of the active ingredient dissolved in an inert liquid carrier. Injection may be either intramuscular, intraruminal, intratracheal, or subcutaneous. The injectable formulation consists of the active ingredient mixed with an appropriate inert liquid carrier. Acceptable liquid carriers include the vegetable oils such as peanut oil, cotton seed oil, sesame oil and the like as well as organic solvents such as solketal, glycerol formal and the like. As an alternative, aqueous parenteral formulations may also be used. The vegetable oils are the preferred liquid carriers. The formulations are prepared by dissolving or suspending the active ingredient in the liquid carrier such that the final formulation contains from 0.005 to 10% by weight of the active ingredient.

Topical application of the compounds active in the method disclosed herein is possible through the use of a liquid drench or a shampoo containing the instant compounds as an aqueous solution, dispersion or suspension. These formulations generally contain a
5 suspending agent such as bentonite, a wetting agent or the like excipient, and normally will also contain an antifoaming agent. Formulations containing from 0.001 to 1% by weight of the active ingredient are acceptable. Preferred formulations are those containing from 0.01 to 1% by weight of the active compounds.

10 The compounds active in the method disclosed herein are primarily useful as antiparasitic agents for the treatment and/or prevention of helminthiasis in domestic animals such as cattle, sheep, horses, dogs, cats, goats, swine, and poultry. They are also useful in the prevention and treatment of parasitic infections of these animals by
15 ectoparasites such as ticks, mites, lice, fleas and the like. They are also effective in the treatment of parasitic infections of humans. In treating such infections the compounds may be used individually or in combination with each other or with other unrelated antiparasitic agents. The dosage of the compounds required for best results depends
20 on several factors such as the species and size of the animal, the type and severity of the infection, the method of administration and the compound used. Oral administration of the compounds at a dose level of from 0.0005 to 10 mg per kg of animal body weight, either in a single dose or in several doses spaced a few days apart, generally gives good results.
25 A single dose of one of the compounds normally gives excellent control however repeat doses may be given to combat re-infection or for parasite species which are unusually persistent. The techniques for administering these compounds to animals are known to those skilled in the veterinary field.

30 The compounds active in the method disclosed herein may also be used to combat agricultural pests which attack crops either in the field or in storage. The compounds are applied for such uses as sprays, dusts, emulsions and the like either to the growing plants or the harvested crops. The techniques for applying these compounds in this
35 manner are known to those skilled in the agricultural arts.

Pharmaceutically useful compositions comprising modulators of the *C. felis* GluCl channel may be formulated according to known methods such as by the admixture of a pharmaceutically acceptable carrier. Examples of such carriers and methods of
5 formulation may be found in Remington's Pharmaceutical Sciences.

The term "chemical derivative" describes a molecule that contains additional chemical moieties which are not normally a part of the base molecule. Such moieties may improve the solubility, half-life, absorption, etc. of the base molecule. Alternatively the moieties may
10 attenuate undesirable side effects of the base molecule or decrease the toxicity of the base molecule. Examples of such moieties are described in a variety of texts, such as Remington's Pharmaceutical Sciences.

The present invention is also directed to methods for screening for compounds which modulate the expression of DNA or
15 RNA encoding *C. felis* GluCl as well as the function of the *C. felis* GluCl protein *in vivo*. Compounds which modulate these activities may be DNA, RNA, peptides, proteins, or non-proteinaceous organic molecules. Compounds may modulate by increasing or attenuating the expression of DNA or RNA encoding *C. felis* GluCl, or the function of the *C. felis*
20 GluCl protein. Compounds that modulate the expression of DNA or RNA encoding *C. felis* GluCl or the function of *C. felis* GluCl protein may be detected by a variety of assays. The assay may be a simple "yes/no" assay to determine whether there is a change in expression or function. The assay may be made quantitative by comparing the
25 expression or function of a test sample with the levels of expression or function in a standard sample. Modulators identified in this process are useful as therapeutic agents, insecticides and anthelmintics.

Kits containing *C. felis* GluCl DNA, antibodies to *C. felis* GluCl, or *C. felis* GluCl protein may be prepared. Such kits are used to
30 detect DNA which hybridizes to *C. felis* GluCl DNA or to detect the presence of *C. felis* GluCl protein or peptide fragments in a sample. Such characterization is useful for a variety of purposes including but not limited to forensic analyses and epidemiological studies.

The DNA molecules, RNA molecules, recombinant protein
35 and antibodies of the present invention may be used to screen and measure levels of *C. felis* GluCl DNA, RNA or protein. The recombinant

proteins, DNA molecules, RNA molecules and antibodies lend themselves to the formulation of kits suitable for the detection and typing of *C. felis* GluCl. Such a kit would comprise a compartmentalized carrier suitable to hold in close confinement at least one container. The
5 carrier would further comprise reagents such as recombinant *C. felis* GluCl protein or anti-GluCl antibodies suitable for detecting GluCl. The carrier may also contain a means for detection such as labeled antigen or enzyme substrates or the like.

Nucleotide sequences that are complementary to the *C. felis*
10 GluCl encoding DNA sequence can be synthesized for antisense therapy. These antisense molecules may be DNA, stable derivatives of DNA such as phosphorothioates or methylphosphonates, RNA, stable derivatives of RNA such as 2'-O-alkylRNA, or other GluCl antisense oligonucleotide mimetics. *C. felis* GluCl antisense molecules may be introduced into
15 cells by microinjection, liposome encapsulation or by expression from vectors harboring the antisense sequence. *C. felis* GluCl antisense therapy may be particularly useful for the treatment of diseases where it is beneficial to reduce GluCl activity.

C. felis GluCl DNA may be used to introduce GluCl into the
20 cells of target organisms. The GluCl gene can be ligated into viral vectors which mediate transfer of the GluCl DNA by infection of recipient host cells. Suitable viral vectors include retrovirus, adenovirus, adeno-associated virus, herpes virus, vaccinia virus, polio virus and the like. Alternatively, GluCl DNA can be transferred into
25 cells by non-viral techniques including receptor-mediated targeted DNA transfer using ligand-DNA conjugates or adenovirus-ligand-DNA conjugates, lipofection membrane fusion or direct microinjection. These procedures and variations thereof are suitable for *ex vivo* as well as *in vivo* GluCl gene therapy. GluCl gene therapy may be particularly useful
30 where it is beneficial to elevate GluCl activity.

The present invention also provides for improved methods of screening for modulators of a GluCl channel in general and modulators of the *C. felis* GluCl channel in particular. It is shown in Example
Section 2 that improved assay conditions result in a 10-fold increase in
35 channel modulator sensitivity when compared to previous known assay conditions. In a preferred aspect of measuring GluCl channel activity,

oocytes are injected with synthetic RNAs or DNAs for one or more *C. felis* GluCl proteins. Following an appropriate period of time to allow for expression, GluCl activity is measured by specific ligand binding and electrophysiological characteristics of the host cells expressing GluCl DNA. Voltage-clamp studies were conducted as described in Example Section 2, preferably utilizing a holding potential of 0 mV during measurements of modulation by ivermectin phosphate. Exemplification of this improved method of a cell-based assay of GluCl channel activity is shown in Example Section 2 and is further detailed in Figures 5A and 5B (showing activation of CfGluCl-1 by glutamate), Figure 6 (showing that the CfGluCl-1 channel is selective for chloride), and Figures 7A and 7B (showing that IVM-PO₄ is an agonist of a GluCl channel).

The following examples are provided to illustrate the present invention without, however, limiting the same hereto.

15

EXAMPLE 1:

Isolation and Characterization of a Full Length cDNA Encoding a *Ctenocephalides felis* GluCl Channel

Ctenocephalides felis Poly A⁺ RNA isolation - Poly(A)⁺ RNA was prepared from whole fleas. The fleas were rapidly frozen in liquid N₂ and ground with a mortar and pestle while submerged in liquid N₂. The frozen, powdered *C. felis* tissue was added to a solution containing 4M guanidinium thiocyanate, 5mM sodium citrate pH 7.0, and 0.1 M β-mercaptoethanol (1gm tissue/10 ml solution), and was mixed with a polytron homogenizer. After 1 minute of homogenization, 0.5% sodium sarkosyl was added and mixed well and the solution was centrifuged at 10,000 rpm for 10 minutes. The supernatant was layered over a 5.7 M CsCl cushion and centrifuged for 18 hours at 33,000 rpm. The RNA pellet was washed with 70% ethanol, resuspended in H₂O and extracted with chloroform:isobutanol, 4:1 and precipitated with ethanol. Poly (A)⁺ RNA was isolated by two rounds of purification on oligo (dT)-cellulose columns.

Isolation of a cDNA Partially Encoding a C.felis GluCl Channel - An oligo-dT primed *C. felis* cDNA library was prepared in the phagemid cloning vector λZAPII (Stratagene, LaJolla, CA) This library

was transfected into *E. coli* PLK-F' cells, plated on NZY medium (Sambrook, et al, 1989, *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY), and incubated 18 hrs. at 37°C. The resultant plaques were

5 transferred to Durulose membranes (Stratagene). The membranes were prehybridized in 50% formamide; 2x Denhardts solution; 5x SSPE; 0.1%SDS; 100µg/ml salmon sperm DNA for 16 hours and hybridized in the above prehybridization solution containing 10% dextran sulfate for 24

10 hours with 2×10^7 cpm a hybridization probe was a PCR-generated fragment of the DrosGluCl cDNA corresponding to nucleotides 471-1760 of the cDNA as listed in GenBank (Cully, et al., 1996, *J. Biol. Chem.* 271(33): 20187-20191; accession number U58776). This DNA codes for all but the last four amino acids of the mature Drosophila glutamate-gated chloride channel. The filters were washed at 52°C in 6xSSC, 0.1% SDS.

15 The washed filters were exposed to X-ray film. Two positive clones, F5A and F6 were chosen for further analysis. These clones were converted into plasmids by *in vivo* excision as per the Stratagene protocol. Clone F5A was subjected to DNA sequence analysis and is disclosed in Figure 3 and SEQ ID NO:3, and as follows:

ATGGACAGCA TTAGTTTGCT CCTACTTTTG ATAACATGTC TAAGTCTACA
 CACATGCTTA TCTGCAAATG CAAAACCTCG TCTAGGAGGC GGCAAAGAAA
 ATTTTCAGGGC CAAAGAAAAG CAAGTTCCTGG ACCAAATTTT AGGCCCAGGC
 5 CATTACGATG CCAGAATAAG GCCTTCTGGA GTCAATGGAA CTGGAATACA
 GTGTCCAGTT AACTTTCAGG GAACAATGGC AGGATGAGAG GTTGAAATTT
 AACGACTTTG GAGGTCGTTT AAAATACTTA ACACTAACCG AAGCAAGTCG
 TGTATGGATG CCCGATTTGT TCTTTGCGAA TGAAAAGGAG GGCCACTTTT
 ACAACATCAT CATGCCGAAC GTCTACATTC GTATTTTTC TACGGTTCC
 10 GTACTATACA GCATCAGGAT ATCGCTTACT TTGGCGTGTC CTATGAATCT
 GAAACTGTAT CCGCTCGATA GGCAGGTGTG CTCTCTCCGG ATGGCCAGTT
 ATGGTTGGAC CACAAACGAT CTGGTGT TGTGGAAGGA AGGTGACCCG
 GTGCAGGTTG TCAAGAATCT ACATCTGCCC AGGTTTACGT TGGAGAAGTT
 CTTGACGGAT TATTGTAACA GCAAAACCAA TACCGGTGAA TACAGTTGCC
 15 TGAAGGTCGA CCTGCTCTTT AAACGAGAGT TCTCGTACTA CCTGATCCAG
 ATCTACATTC CTTGTTGCAT GTTGGTGATC GTTTCCTGGG TGTCGTTCTG
 GTTGGACCAG GGAGCGGTTT CGGCCAGAGT ATCACTGGGT GTGACCACTC
 TCCTCACCAT GGCCACCCAG ACGTCGGGCA TAAACGCCTC CCTGCCGCCA
 GTGTCCTACA CAAAAGCCAT CGACGTCTGG ACCGGAGTCT GCCTCACGTT
 20 CGTCTTCGGG GCTTTGCTCG AATTCGCCCT CGTCAACTAC GCCTCCAGAT
 CCGATATGCA CAGGGAAAAC ATGAAGAAAA AGCGCAGGGA ACTTGAACAA
 GCAGCCAGCC TGGACGCCGC CTCCGACCTG ATGGACGGCA CTGATGGCAC
 TTTTGCTATG AAGCCTCTGG TACGCCACTC CGTCGACGCC GTCGGTCTCG
 ATAAGGTTTCG TCAGTGCGAG ATACACATGC AGCCGGCGTC CAGGCAGAAC
 25 TGCTGCAGGA GCTGGATAAG CAAATTCCCG ACGAGGTCGA AACGCATCGA
 CGTCATATCA AGAATCACTT TCCCCTGGT GTTTGCTTTG TTCAATCTGG
 TGTAATGGTC GACCTATTTG TTCAGGGACG AGGCGGAGGA GAATTAG
 (SEQ ID NO:3) .

30 Clone F5A was shown to encode a truncated polypeptide disclosed in
 Figure 4 and SEQ ID NO:4, referred to within this specification as
 trCfGluCl-1, and disclosed as follows:

35

1 MDSISLLLLL ITCLSLHTCL SANAKPRLGG GKENFRAKEK QVLDQILGPG
 51 HYDARIRPSG VNGTGIQCPV NFQGT MAG (SEQ ID NO:4) .

Isolation of a cDNA Encoding a C. felis GluCl Channel - It
 5 was determined that clone F5A lacked an internal portion a possible *C. felis* GluCl channel cDNA at the presumptive amino-terminal extracellular domain, resulting in a frame shift mutation and the concomitant truncated protein, trCfGluCl-1. A cDNA fragment containing the missing portion of a putative *C. felis* GluCl channel
 10 cDNA was generated by PCR amplification of randomly primed flea cDNA. Primer-1 (CTCAGAGTCAGGATCCGGCTA; SEQ ID NO:5) and Primer-2 (CTGAAAGTTAACTGGACACTG; SEQ ID NO:6) were used in a standard PCR reaction to amplify a 532 bp PCR fragment that was shown by DNA sequence analysis to contain the missing 71 nucleotides
 15 and flanking sequences disclosed in the F5A clone. This PCR fragment is as follows:

TCAGAGTCA G GATCC GGCTA TATTGGACGA TATGCTGCAT GGTCCCTGTC
 ATACAAATAC TCCTTCGCCT TCACTGGAAC CAACCAAGAC TGTCCCCACG
 20 TGTCCGACAT CAGTTGAAGG AAATTCTGTG ACGACATGGC AACACTTTTG
 TTCAGGAACA ACAATAACAT CATCGACACA GAATATCGGC GAAGCCTATT
 CTTCGATTCA AGAAGAAGAA TTTCTTCACT TTATCTTCAG GGATGGACAG
 CATTAGTTTG CTCCTACTTT TGATAACATG TCTAAGTCTA CACACATGCT
 TATCTGCAAA TGCAAAACCT CGTCTAGGAG GCGGCAAAGA AAATTTTCAGG
 25 GCCAAAGAAA AGCAAGTTCT GGACCAAATT TTAGGCCAG GCCATTACGA
 TGCCAGAATA AGGCCTTCTG GAGTCAATGG AACTGGAGAC GGTCCGACCG
 TGGTAGCAGT CAACATCTAT CTGAGATCAA TCAGCGAAAT AGATGACTAC
 AAAATGGAAT ACAGTGTCCA GTTAAC TTTC AG (SEQ ID NO:8)

30 This PCR fragment was cloned using the TA cloning vector kit (Invitrogen) and individual clones were sequenced to identify those lacking PCR artifacts and containing the missing 71 bp fragment. A 517 bp BamHI/HpaI fragment (Bam HI-GGATCC; HpaI GTTAAC, as underlined above) of this PCR product was isolated and inserted into a
 35 BamHI/HpaI digested F5A clone (Figure 3; SEQ ID NO:3) to generate the

full length cDNA clone in the F5A pBS vector, designated Flea51, shown in Figure 1, and set forth as SEQ ID NO:1 as follows:

```

5   ATGGACAGCA TTAGTTTGCT CCTACTTTTG ATAACATGTC TAAGTCTACA
    CACATGCTTA TCTGCAAATG CAAAACCTCG TCTAGGAGGC GGCAAAGAAA
    ATTTTCAGGGC CAAAGAAAAG CAAGTTCTGG ACCAAATTTT AGGCCCAGGC
    CATTACGATG CCAGAATAAG GCCTTCTGGA GTCAATGGAA CTGGAGACGG
    TCCGACCGTG GTAGCAGTCA ACATCTATCT GAGATCAATC AGCGAAATAG
    ATGACTACAA AATGGAATAC AGTGTCCAGT TAACTTTCAG GGAACAATGG
10  CAGGATGAGA GGTGAAATT TAACGACTTT GGAGGTCGTT TAAAATACTT
    AACACTAACC GAAGCAAGTC GTGTATGGAT GCCCGATTTG TTC'TTTGCGA
    ATGAAAAGGA GGGCCACTTT CACAACATCA TCATGCCGAA CGTCTACATT
    CGTATTTTTC CTTACGGTTC CGTACTATAC AGCATCAGGA TATCGCTTAC
    TTTGGCGTGT CCTATGAATC TGAAACTGTA TCCGCTCGAT AGGCAGGTGT
15  GCTCTCTCCG GATGGCCAGT TATGGTTGGA CCACAAACGA TCTGGTGT'TT
    TTGTGGAAGG AAGGTGACCC GGTGCAGGTT GTCAAGAATC TACATCTGCC
    CAGGTTTACG TTGGAGAAGT TCTTGACGGA TTATTGTAAC AGCAAAACCA
    ATACCGGTGA ATACAGTTGC CTGAAGGTCG ACCTGCTCTT TAAACGAGAG
    TTCTCGTACT ACCTGATCCA GATCTACATT CCTTGTTGCA TGT'TGGTGAT
20  CGTTTCCTGG GTGTCGTTCT GGT'TGGACCA GGGAGCGGTT CCGGCCAGAG
    TATCACTGGG TGTGACCACT CTCCTACCA TGGCCACCCA GACGTCGGGC
    ATAAACGCCT CCCTGCCGCC AGTGTCTTAC ACAAAGCCA TCGACGTCTG
    GACCGGAGTC TGCCTCACGT TCGTCTTCGG GGCTTTGCTC GAATTCGCCC
    TCGTCAACTA CGCCTCCAGA TCCGATATGC ACAGGGAAAA CATGAAGAAA
25  AAGCGCAGGG AACTTGAACA AGCAGCCAGC CTGGACGCCG CCTCCGACCT
    GATGGACGGC ACTGATGGCA CTTT'TGCTAT GAAGCCTCTG GTACGCCACT
    CCGTCTGACG CGTCGGTCTC GATAAGGTTC GTCAGTGC GAATACACATG
    CAGCCGGCGT CCAGGCAGAA CTGCTGCAGG AGCTGGATAA GCAAATTCCC
    GACGAGGTCG AAACGCATCG ACGTCATATC AAGAATCACT TTCCCGCTGG
30  TGTTTGCTTT GTTCAATCTG GTGTACTGGT CGACCTATTT GTTCAGGGAC
    GAGGCGGAGG AGAATTAG (SEQ ID NO:1).

```

This cDNA molecule contains an open reading frame which encodes a *C. felis* GluCl channel, as shown in Figure 2, as set forth as SEQ ID

NO:2, and as follows:

MDSISLLLLL ITCLSLHTCL SANAKPRLGG GKENFRAKEK QVLDQILGPG
 HYDARIRPSG VNGTGDGPTV VAVNIYLRSI SEIDDYKMEY SVQLTFREQW
 QDERLKFNDF GGRLKYLTLT EASRVWMPDL FFANEKEGHF HNIIMPVNI
 RIFPYGSVLY SIRISLTLAC PMNLKLYPLD RQVCSLRMAS YGWTITNDLVF
 5 LWKEGDPVQV VKNLHLPRFT LEKFLTIDYCN SKTNTGEYSC LKVDLLFKRE
 FSYYLIQIYI PCCMLVIVSW VSFWLDQGAV PARVSLGVTT LLTMTATQTS
 INASLPPVSY TKRIDVWTV CLTFVFGALL EFALVNYASR SDMHRENMKK
 KRRELEQAAS LDAASDLMDG TDGTFAMKPL VRHSVDAVGL DKVRQCEIHM
 QPASRQNCRR SWISKFPTRS KRIDVISRIT FPLVFALFNL VYWSTYLFDR
 10 EAEEN (SEQ ID NO:2).

In addition, the 5' untranslated region the exemplified cDNA which encodes a CfGluCl channel protein was determined and is presented as SEQ ID NO:7, and as follows:

15 AACTAGTGGA TCCCCCGGGC TGCAGGATTC GGCACGAGAA TTTTTTAAAA
 TAATCCTCAA CAGCATGATA CAAGAGGATG ATTTTATGAT CCCTGTAAAC
 ACTTGCTTGA ATTTTAGATT GCAACTGGAG GCTCCGCTGA CACTCTCTCT
 TGTTCGAGCA CAGGAATTGC TCGACATCTG GTCAAACGCG GGCTACTTCA
 20 TAATATCCGA CGATGACAAT TTAATGTTCG GAGCAAGAAC AATTGCAGAA
 TTTGAAGTGT ACTTTAACGA TACATTCGAA GGACGCATGA AAATGTGCAC
 GATGTGCATG TTGCCCACCT TCTATTGACC AGCAAGCACC CCTTCGCCCG
 TGAGCATGTC ACCCACCAGC AGGCGCCTTC TGTGCGCCCT CGACGACCTG
 CACTTAGCGG TTGCTAAGAA GCCCTAAGAA GCCGAGACGG TTCGCTTCGC
 25 CCGGGGGCGA TTCCTCACGA TGCACAAGCG GAGGCGCAAG AGGCTGACGA
 CGAGGAGCCT CAGAGTCAGG ATCCGGCTAT ATTGGACGAT ATGCTGCATG
 GTCCCTGTCA TACAAATACT CCTTCGCCTT CACTGGAACC AACCAAGACT
 GTCCCCACGT GTCCGACATC AGTTGAAGGA AATCTGTGA CGACATGGCA
 AACTTTTTGT TCAGGAACAA CAATAACATC ATCGACACAG AATATCGGCG
 30 AAGCCTATTC TTCGATTCAA GAAGAAGAAT TTCTTCACTT TATCTTCAGG
 G (SEQ ID NO:7)

EXAMPLE 2

Expression of the CfGluCl-1 protein in *Xenopus* oocytes

The full-length cDNA encoding CfGluCl-1 in plasmid vector pBluescript (Stratagene, LaJolla, CA) is linearized and capped cRNA transcripts are synthesized using appropriate oligonucleotide primers and the mMESSAGE mMACHINE *in vitro* RNA transcription kit (Ambion). *Xenopus laevis* oocytes were prepared and injected using standard methods as described (Arena et al., 1991, *Mol. Pharmacol.* 40: 368-374; Arena et al, 1992, *Mol. Brain Res.* 15: 339-348). Adult female *Xenopus laevis* were anesthetized with 0.17% tricaine methanesulfonate and the ovaries were surgically removed and placed in a dish consisting of (mM): NaCl 82.5, KCl 2, MgCl₂ 1, CaCl₂ 1.8, HEPES 5 adjusted to pH 7.5 with NaOH (OR-2). Ovarian lobes were broken open, rinsed several times, and gently shaken in OR-2 containing 0.2% collagenase (Sigma, Type 1A) for 2-5 hours. When approximately 50% of the follicular layers were removed, Stage V and VI oocytes were selected and placed in media consisting of (mM): NaCl 86, KCl 2, MgCl₂ 1, CaCl₂ 1.8, HEPES 5, Na pyruvate 2.5, theophylline 0.5, gentamicin 0.1 adjusted to pH 7.5 with NaOH (ND-96) for 24-48 hours before injection. For most experiments, oocytes were injected with 10 ng of cRNA in 50 nl of RNase free water. Control oocytes were injected with 50 nl of water. Oocytes were incubated for 1-5 days in ND-96 supplemented with 50 mg/ml gentamycin, 2.5 mM Na pyruvate and 0.5 mM theophylline before recording. Incubations and collagenase digestion were carried out at 18° C.

Voltage-clamp studies were conducted with the two microelectrode voltage clamp technique using a Dagan CA1 amplifier (Dagan Instruments, Minneapolis, MN). The current passing microelectrodes were filled with 0.7 M KCl plus 1.7 M K₃-citrate and the voltage recording microelectrodes were filled with 1.0 M KCl. The extracellular solution for most experiments was saline consisting of (mM): NaCl 96, BaCl₂ 3.5, MgCl₂ 0.5, CaCl₂ 0.1, HEPES 5, adjusted to pH 7.5 with NaOH. The extracellular chloride concentration was

reduced in some experiments by equimolar replacement of NaCl with the sodium salt of the indicated anion. Experiments were conducted at 21-24 ° C. Data were acquired using the program Pulse and most analysis was performed with the companion program Pulsefit
5 (Instrutech Instruments, Great Neck, NY) or with Igor Pro (Wavemetrics, Lake Oswego, OR). Data were filtered (f_c , -3db) at 1 kHz, unless otherwise indicated.

Figure 5A and Figure 5B show the activation of CfGluCl-1 by glutamate. Figure 5A shows superimposed current recordings in
10 response to 10, 30, 100 and 300 μ M glutamate. The duration of exposure to glutamate is indicated by the solid bar at top. Figure 5B shows the concentration-response curve for glutamate. Peak outward current is plotted vs. glutamate concentration. The solid curve is the best fit to the equation $I/I_{\max} = \{1 + (EC_{50}/[\text{glutamate}])^n\}^{-1}$. For the
15 experiment shown in Figure 5B, $EC_{50} = 9.3 \mu\text{M}$, $n = 2.13$. Agonists for other types of ligand-gated chloride channels were also tested for the ability to activate CfGluCl-1. GABA, glycine, histamine, acetylcholine and muscimol were all inactive.

20 Figure 6 shows that the CfGluCl-1 channel is selective for chloride. Each curve represents the difference between the current measured with and without 10 μ M glutamate. The voltage was ramped from -120 to +60 mV at 1 volt/second. Chloride concentration was reduced from 104 mM to 8.2 mM by equimolar substitution of NaCl by
25 Na-methanesulfonate or Na-gluconate. Each current-voltage relationship was fit to a seventh order polynomial using non-linear least squares analysis and the reversal potential was taken as the x-intercept of this polynomial. The reversal potential measurements indicate that the relative permeability for methanesulfonate (i.e., (permeability for
30 methanesulfonate)/ (permeability for chloride)) is 0.218 and the relative permeability for gluconate is 0.064.

Figures 7A and B show that ivermectin phosphate is an agonist of the flea GluCl channel encoded by CfGluCl-1. Figure 7A shows activation of CfGluCl-1 by ivermectin phosphate (IVM- PO_4) and
35 superimposed current recordings showing activation by 100 μ M glutamate and 10 nM IVM- PO_4 . The activation by IVM- PO_4 has a

sigmoidal onset suggesting that multiple binding sites must be occupied for opening. Figure 7B shows the concentration-response curve for IVM-PO₄. A single [IVM-PO₄] was tested on each oocyte. The ordinate is the maximal current induced by IVM-PO₄ normalized by the peak

5 current induced by 100 μM glutamate, a maximally effective concentration. The error bars indicate ±S.E.M. The holding potential was 0 mV for both sets of measurements. The filled circles represent data for CfGluCl-1. The solid curve is the best fit to this data by

(1)
$$I = I_{ivm,max} / (1 + (EC_{50}/[IVM-PO_4])^n)$$

10 where $I_{ivm,max} = 0.718$, $EC_{50} = 2.93$ nM, and $n = 1.0$.

Also shown is the dose-response curve previously reported for the DmGluCl1 clone from *Drosophila melanogaster*, except that in these earlier studies the holding potential was -80 mV (Cully et al., J. 1996, *J. Biol. Chem.* 271: 20187-20191). This curve is the best fit to equation (1) for

15 modification by IVM-PO₄, where $I_{ivm,max} = 0.35$, $EC_{50} = 41$ nM, and $n = 1.2$. This data shows a 10-fold increase in potency. Additional data shows that this increase in potency is not the result of differences between the clones and/or in measurement technique. The measurements were repeated on DmGluCl1 at a holding potential of 0

20 mV (filled squares); the solid curve is the best fit to equation (1) with the constraint that the EC_{50} and n are the same as for CfGluCl1. The goodness of fit indicates that the EC_{50} for DmGluCl1 is similar to that for CfGluCl1 and that both channels are activated by IVM-PO₄ at concentrations 10-fold lower than previously recognized.

WHAT IS CLAIMED:

1. A purified DNA molecule encoding a *C. felis* GluClu
 5 channel protein wherein said protein comprises the amino acid
 sequence as follows:

10 MDSISLLLLL ITCLSLHTCL SANAKPRLGG GKENFRAKEK QVLDQILGPG
 HYDARIRPSG VNGTGDGPTV VAVNIYLRSI SEIDDYKMEY SVQLTFREQW
 QDERLKFNDG GGRLLKYLTLT EASRVWMPDL FFANEKEGHF HNIIMPVYI
 RIFPYGSVLY SIRISLTLAC PMNLKLYPLD RQVCSLRMAS YGWTNDLVF
 LWKEGDPVQV VKNLHLPRFT LEKFLTDYCN SKTNTGEYSC LKVDLLFKRE
 FSYYLIQIYI PCCMLVIVSW VSFWLDQGAV PARVSLGVTT LLTMATQTSG
 INASLPPVSY TKRIDVWTGV CLTFVFGALL EFALVNYASR SDMHRENMKK
 KRRELEQAAS LDAASDLMDG TDGTFAMKPL VRHSVDAVGL DKVRQCEIHM
 15 QPASRQNCCR SWISKFPTRS KRIDVISRIT FPLVFALFNL VYWSTYLFDRD
 EAEEN,

as set forth in three-letter abbreviation in SEQ ID NO:2.

2. An expression vector for expressing a *C. felis* GluClu
 20 channel protein in a recombinant host cell wherein said expression
 vector comprises a DNA molecule of claim 1.

3. A host cell which expresses a recombinant *C. felis*
 GluClu channel protein wherein said host cell contains the expression
 25 vector of claim 2.

4. A process for expressing a *C. felis* GluClu channel
 protein in a recombinant host cell, comprising:

- 30 (a) transfecting the expression vector of claim 2 into a
 suitable host cell; and,

- (b) culturing the host cells of step (a) under
 conditions which allow expression of said *C. felis* GluClu channel
 35 protein from said expression vector.

5. A purified DNA molecule encoding a *C. felis* GluClu channel protein wherein said protein consists of the amino acid sequence as follows:

5 MDSISLLLLL ITCLSLHTCL SANAKPRLGG GKENFRAKEK QVLDQILGPG
 , HYDARIRPSG VNGTGDGPTV VAVNIYLRSI SEIDDYKMEY SVQLTFREQW
 QDERLKFNDF GGRLKYLTLT EASRVWMPDL FFANEKEGHF HNIIMPVYI
 RIFPYGSVLY SIRISLTLAC PMNLKLYPLD RQVCSLRMAS YGWTTNDLVF
 LWKEGDPVQV VKNLHLPRFT LEKFLTDYCN SKTNTGEYSC LKVDLLFKRE
 FSYYLIQIYI PCCMLVIVSW VSFWLDQGAV PARVSLGVTT LLTMATQTSG
 10 INASLPPVSY TKAIDVWTGV CLTFVFGALL EFALVNYASR SDMHRENMKK
 KRRELEQAAS LDAASDLMDG TDGTFAMKPL VRHSVDAVGL DKVRQCEIHM
 QPASRQNCRR SWISKFPTRS KRIDVISRIT FPLVFALFNL VYWSTYLFRD
 EAEEN,

as set forth in three-letter abbreviation in SEQ ID NO:2.

15

6. An expression vector for expressing a *C. felis* GluClu channel protein in a recombinant host cell wherein said expression vector comprises a DNA molecule of claim 5.

20

7. A host cell which expresses a recombinant *C. felis* GluClu channel protein wherein said host cell contains the expression vector of claim 6.

25

8. A process for expressing a *C. felis* GluClu channel protein in a recombinant host cell, comprising:

(a) transfecting the expression vector of claim 6 into a suitable host cell; and,

30

(b) culturing the host cells of step (a) under conditions which allow expression of said *C. felis* GluClu channel protein from said expression vector.

35

9. A purified DNA molecule encoding a recombinant *C. felis* GluClu channel protein wherein said DNA molecule comprises the nucleotide sequence as set forth in SEQ ID NO:1, as follows:

ATGGACAGCA TTAGTTTGCT CCTACTTTTG ATAACATGTC TAAGTCTACA
 CACATGCTTA TCTGCAAATG CAAAACCTCG TCTAGGAGGC GGCAAAGAAA
 ATTTACAGGC CAAAGAAAAG CAAGTTCTGG ACCAAATTTT AGGCCCAGGC
 CATTACGATG CCAGAATAAG GCCTTCTGGA GTCAATGGAA CTGGAGACGG
 5 TCCGACCGTG GTAGCAGTCA ACATCTATCT GAGATCAATC AGCGAAATAG
 ATGACTACAA AATGGAATAC AGTGTCCAGT TAACTTTCAG GGAACAATGG
 CAGGATGAGA GGTGAAATT TAACGACTTT GGAGGTCGTT TAAAATACTT
 AACACTAACC GAAGCAAGTC GTGTATGGAT GCCCATTGTT TTCTTTGCGA
 ATGAAAAGGA GGGCCACTTT CACAACATCA TCATGCCGAA CGTCTACATT
 10 CGTATTTTTC CTTACGGTTC CGTACTATAC AGCATCAGGA TATCGCTTAC
 TTTGGCGTGT CCTATGAATC TGAAACTGTA TCCGCTCGAT AGGCAGGTGT
 GCTCTCTCCG GATGGCCAGT TATGGTTGGA CCACAAACGA TCTGGTGTTT
 TTGTGGAAGG AAGGTGACCC GGTGCAGGTT GTCAAGAATC TACATCTGCC
 CAGGTTTACG TTGGAGAAGT TCTTGACGGA TTATTGTAAC AGCAAAACCA
 15 ATACCGGTGA ATACAGTTGC CTGAAGGTCG ACCTGCTCTT TAAACGAGAG
 TTCTCGTACT ACCTGATCCA GATCTACATT CCTTGTTGCA TGTTGGTGAT
 CGTTTCCTGG GTGTCGTTCT GGTGACCA GGGAGCGGTT CCGGCCAGAG
 TATCACTGGG TGTGACCACT CTCCTCACCA TGGCCACCCA GACGTCGGGC
 ATAAACGCCT CCCTGCCGCC AGTGTCTTAC ACAAAGCCA TCGACGTCTG
 20 GACCGGAGTC TGCCTCACGT TCGTCTTCGG GGCTTTGCTC GAATTCGCCC
 TCGTCAACTA CGCCTCCAGA TCCGATATGC ACAGGGAAAA CATGAAGAAA
 AAGCGCAGGG AACTTGAACA AGCAGCCAGC CTGGACGCCG CCTCCGACCT
 GATGGACGGC ACTGATGGCA CTTTTGCTAT GAAGCCTCTG GTACGCCACT
 CCGTCGACGC CGTCGGTCTC GATAAGGTTT GTCAGTGCGA GATACACATG
 25 CAGCCGGCGT CCAGGCAGAA CTGCTGCAGG AGCTGGATAA GCAAATTCCC
 GACGAGGTCG AAACGCATCG ACGTCATATC AAGAATCACT TTCCCGCTGG
 TGTTTGCTTT GTTCAATCTG GTGTACTGGT CGACCTATTT GTTCAGGGAC
 GAGGCGGAGG AGAATTAG,
 (SEQ ID NO:1).
 30

10. An expression vector for expressing a recombinant *C. felis* GluClu channel protein wherein said expression vector comprises a DNA molecule of claim 9.

11. A host cell which expresses a recombinant recombinant *C. felis* GluClu channel protein wherein said host cell contains the expression vector of claim 10.

5 12. A process for expressing a recombinant *C. felis* GluClu channel protein in a recombinant host cell, comprising:

(a) transfecting the expression vector of claim 10 into a suitable host cell; and,

10

(b) culturing the host cells of step (a) under conditions which allow expression of said recombinant *C. felis* GluClu channel protein from said expression vector.

15 13. A purified DNA molecule encoding a recombinant *C. felis* GluClu channel protein wherein said DNA molecule consists of the nucleotide sequence as set forth in SEQ ID NO:1, as follows:

ATGGACAGCA TTAGTTTGCT CCTACTTTTG ATAACATGTC TAAGTCTACA
CACATGCTTA TCTGCAAATG CAAAACCTCG TCTAGGAGGC GGCAAAGAAA
20 ATTTTCAGGGC CAAAGAAAAG CAAGTTCTGG ACCAAATTTT AGGCCCAGGC
CATTACGATG CCAGAATAAG GCCTTCTGGA GTCAATGGAA CTGGAGACGG
TCCGACCGTG GTAGCAGTCA ACATCTATCT GAGATCAATC AGCGAAATAG
ATGACTACAA AATGGAATAC AGTGTCCAGT TAACTTTCAG GGAACAATGG
CAGGATGAGA GGTTGAAATT TAACGACTTT GGAGGTCGTT TAAATACTTT
25 AACACTAACC GAAGCAAGTC GTGTATGGAT GCCCGATTTG TTCTTTGCGA
ATGAAAAGGA GGGCCACTTT CACAACATCA TCATGCCGAA CGTCTACATT
CGTATTTTTTC CTTACGGTTC CGTACTATAC AGCATCAGGA TATCGCTTAC
TTTGGCGTGT CCTATGAATC TGAAACTGTA TCCGCTCGAT AGGCAGGTGT
GCTCTCTCCG GATGGCCAGT TATGGTTGGA CCACAAACGA TCTGGTGTTT
30 TTGTGGAAGG AAGGTGACCC GGTGCAGGTT GTCAAGAATC TACATCTGCC
CAGGTTTACG TTGGAGAAGT TCTTGACGGA TTATTGTAAC AGCAAAACCA
ATACCGGTGA ATACAGTTGC CTGAAGGTCG ACCTGCTCTT TAAACGAGAG
TTCTCGTACT ACCTGATCCA GATCTACATT CCTTGTTGCA TGTGTTGAT
CGTTTCCTGG GTGTCGTTCT GGTGACCA GGGAGCGGTT CCGGCCAGAG
35 TATCACTGGG TGTGACCACT CTCCTACCA TGGCCACCCA GACGTCGGGC
ATAAACGCCT CCCTGCCGCC AGTGTCTTAC ACAAAGCCA TCGACGTCTG

GACCGGAGTC TGCCTCACGT TCGTCTTCGG GGCTTTGCTC GAATTCGCCC
 TCGTCAACTA CGCCTCCAGA TCCGATATGC ACAGGGAAAA CATGAAGAAA
 AAGCGCAGGG AACTTGAACA AGCAGCCAGC CTGGACGCCG CCTCCGACCT
 GATGGACGGC ACTGATGGCA CTTTTGCTAT GAAGCCTCTG GTACGCCACT
 5 CCGTCGACGC CGTCGGTCTC GATAAGGTTT GTCAGTGCGA GATACACATG
 CAGCCGGCGT CCAGGCAGAA CTGCTGCAGG AGCTGGATAA GCAAATTCCC
 GACGAGGTCG AAACGCATCG ACGTCATATC AAGAATCACT TTCCCGCTGG
 TGTTCGCTTT GTTCAATCTG GTGTACTGGT CGACCTATTT GTTCAGGGAC
 GAGGCGGAGG AGAATTAG,
 10 (SEQ ID NO:1) .

14. An expression vector for expressing a recombinant *C. felis* GluClu channel protein wherein said expression vector comprises a DNA molecule of claim 13.

15 15. A host cell which expresses a recombinant recombinant *C. felis* GluClu channel protein wherein said host cell contains the expression vector of claim 14.

20 16. A process for expressing a recombinant *C. felis* GluClu channel protein in a recombinant host cell, comprising:

(a) transfecting the expression vector of claim 14 into a suitable host cell; and,

25 (b) culturing the host cells of step (a) under conditions which allow expression of said recombinant *C. felis* GluClu channel protein from said expression vector.

30 17. A purified DNA molecule encoding a truncated portion of a *C. felis* GluClu channel protein wherein said protein consists of the amino acid sequence as follows:

MDSISLLLLL ITCLSLHTCL SANAKPRLGG GKENFRAKEK QVLDQILGPG
 HYDARIRPSG VNGTGIQCPV NFQGTMAAG,

35 as set forth in three-letter abbreviation in SEQ ID NO:4.

18. An expression vector for expressing a *C. felis* GluClu channel protein in a recombinant host cell wherein said expression vector comprises a DNA molecule of claim 17.

5 19. A host cell which expresses a recombinant *C. felis* GluClu channel protein wherein said host cell contains the expression vector of claim 18.

10 20. A process for expressing a *C. felis* GluClu channel protein in a recombinant host cell, comprising:

(a) transfecting the expression vector of claim 18 into a suitable host cell; and,

15 (b) culturing the host cells of step (a) under conditions which allow expression of said *C. felis* GluClu channel protein from said expression vector.

20 21. A purified DNA molecule encoding a recombinant *C. felis* GluClu channel protein wherein said DNA molecule consists of the nucleotide sequence as set forth in SEQ ID NO:3, as follows:

25 ATGGACAGCA TTAGTTTGCT CCTACTTTTG ATAACATGTC TAAGTCTACA
CACATGCTTA TCTGCAAATG CAAAACCTCG TCTAGGAGGC GGCAAAGAAA
ATTTTCAGGGC CAAAGAAAAG CAAGTTCTGG ACCAAATTTT AGGCCCAGGC
CATTACGATG CCAGAATAAG GCCTTCTGGA GTCAATGGAA CTGGAATACA
GTGTCCAGTT AACTTTCAGG GAACAATGGC AGGATGAGAG GTTGAAATTT
AACGACTTTG GAGGTCGTTT AAAATACTTA AACTAACCG AAGCAAGTCG
TGTATGGATG CCCGATTTGT TCTTTGCGAA TGAAAAGGAG GGCCACTTTC
ACAACATCAT CATGCCGAAC GTCTACATTC GTATTTTTCCT TTACGGTTCC
30 GTACTATACA GCATCAGGAT ATCGCTTACT TTGGCGTGTC CTATGAATCT
GAAACTGTAT CCGCTCGATA GGCAGGTGTG CTCTCTCCGG ATGGCCAGTT
ATGGTTGGAC CACAAACGAT CTGGTGTTTT TGTGGAAGGA AGGTGACCCG
GTGCAGGTTG TCAAGAATCT ACATCTGCCC AGGTTTACGT TGGAGAAGTT
CTTGACGGAT TATTGTAACA GCAAACCAA TACCGGTGAA TACAGTTGCC
35 TGAAGGTCGA CCTGCTCTTT AAACGAGAGT TCTCGTACTA CCTGATCCAG
ATCTACATTC CTTGTTGCAT GTTGGTGATC GTTTCCTGGG TGTCGTTCTG

GTTGGACCAG GGAGCGGTTC CGGCCAGAGT ATCACTGGGT GTGACCACTC
 TCCTCACCAT GGCCACCCAG ACGTCGGGCA TAAACGCCTC CCTGCCGCCA
 GTGTCCTACA CAAAAGCCAT CGACGTCTGG ACCGGAGTCT GCCTCACGTT
 CGTCTTCGGG GCTTTGCTCG AATTCGCCCT CGTCAACTAC GCCTCCAGAT
 5 CCGATATGCA CAGGGAAAAC ATGAAGAAAA AGCGCAGGGA ACTTGAACAA
 GCAGCCAGCC TGGACGCCGC CTCCGACCTG ATGGACGGCA CTGATGGCAC
 TTTTGCTATG AAGCCTCTGG TACGCCACTC CGTCGACGCC GTCGGTCTCG
 ATAAGGTTCG TCAGTGCGAG ATACACATGC AGCCGGCGTC CAGGCAGAAC
 TGCTGCAGGA GCTGGATAAG CAAATTCCCG ACGAGGTCGA AACGCATCGA
 10 CGTCATATCA AGAATCACTT TCCCCTGGT GTTTGCTTTG TTCAATCTGG
 TGTACTGGTC GACCTATTTG TTCAGGGACG AGGCGGAGGA GAATTAG,
 (SEQ ID NO:3).

22. An expression vector for expressing a recombinant *C. felis*
 15 *GluClu* channel protein wherein said expression vector comprises
 a DNA molecule of claim 21.

23. A host cell which expresses a recombinant *C. felis*
GluClu channel protein wherein said host cell contains the expression
 20 vector of claim 22.

24. A process for expressing a recombinant *C. felis*
GluClu channel protein in a recombinant host cell, comprising:
 25 (a) transfecting the expression vector of claim 22 into
 a suitable host cell; and,

(b) culturing the host cells of step (a) under
 conditions which allow expression of said recombinant *C. felis* *GluClu*
 30 channel protein from said expression vector.

25. A *C. felis* *GluClu* channel protein free from
 other *C. felis* proteins which comprises the amino acid sequence set forth
 in SEQ ID NO:2.
 35

26. A *C. felis* GluClu channel protein of claim 25 which is a product of a DNA expression vector contained within a recombinant host cell.

5 27. A membrane preparation purified from a recombinant host cell of claim 26.

28. A truncated *C. felis* GluClu channel protein free from other *C. felis* proteins which comprises the amino acid
10 sequence set forth in SEQ ID NO:4.

29. A truncated *C. felis* GluClu channel protein of claim 28 which is a product of a DNA expression vector contained within a recombinant host cell.

15 30. A membrane preparation purified from a recombinant host cell of claim 29.

31. A method of identifying a compound that modulates
20 glutamate-gated channel protein activity, which comprises:

a) injecting into a host cell solution a population of nucleic acid molecules, at least of portion of which encode a glutamate-gated channel protein, such that expression of said portion of nucleic
25 acid molecules results in an active glutamate-gated channel;

b) adding a test compound into said solution;

c) measuring host cell membrane current at a holding
30 potential more positive than the reversal potential for chloride.

32. The method of Claim 31 wherein said glutamate gated channel protein is selected from the group consisting of *Caenorhabditis elegans*, *Drosophila melanogaster* and *Ctenocephalides felis* glutamate-gated channel proteins.
35

33. The method of claim 32 wherein said nucleic acid molecule is selected from the group consisting of complementary DNA, poly A⁺ messenger RNA and complementary RNA.

5 34. The method of claim 32 wherein said holding potential is 0 mV.

1/8

1 ATGGACAGCA TTAGTTTGCT CCTACTTTTG ATAACATGTC TAAGTCTACA
51 CACATGCTTA TCTGCAAATG CAAAACCTCG TCTAGGAGGC GGCAAAGAAA
101 ATTTCAAGGC CAAAGAAAAG CAAGTTCTGG ACCAAATTTT AGGCCCAGGC
151 CATTACGATG CCAGAATAAG GCCTTCTGGA GTCAATGGAA CTGGAGACGG
201 TCCGACCGTG GTAGCAGTCA ACATCTATCT GAGATCAATC AGCGAAATAG
251 ATGACTACAA AATGGAATAC AGTGTCCAGT TAACTTTCAG GGAACAATGG
301 CAGGATGAGA GGTTGAAATT TAACGACTTT GGAGGTCGTT TAAAATACTT
351 AACACTAACC GAAGCAAGTC GTGTATGGAT GCCCGATTG TTCTTTGCGA
401 ATGAAAAGGA GGGCCACTTT CACAACATCA TCATGCCGAA CGTCTACATT
451 CGTATTTTTT CTTACGGTTC CGTACTATAC AGCATCAGGA TATCGCTTAC
501 TTTGGCGTGT CCTATGAATC TGAAACTGTA TCCGCTCGAT AGGCAGGTGT
551 GCTCTCTCCG GATGGCCAGT TATGGTTGGA CCACAAACGA TCTGGTGTTT
601 TTGTGGAAGG AAGGTGACCC GGTGCAGGTT GTCAAGAATC TACATCTGCC
651 CAGGTTTACG TTGGAGAAGT TCTTGACGGA TTATTGTAAC AGCAAAACCA
701 ATACCGGTGA ATACAGTTGC CTGAAGGTCG ACCTGCTCTT TAAACGAGAG
751 TTCTCGTACT ACCTGATCCA GATCTACATT CCTTGTTGCA TGTTGGTGAT
801 CGTTTCCTGG GTGTCGTTCT GGTGGACCA GGGAGCGGTT CCGGCCAGAG
851 TATCACTGGG TGTGACCACT CTCCTACCA TGGCCACCCA GACGTCGGGC
901 ATAAACGCCT CCCTGCCGCC AGTGTCTTAC ACAAAGCCA TCGACGTCTG

FIG.1A

2/8

951 GACCGGAGTC TGCCTCACGT TCGTCTTCGG GGCTTTGCTC GAATTCGCCC
1001 TCGTCAACTA CGCCTCCAGA TCCGATATGC ACAGGGAAAA CATGAAGAAA
1051 AAGCGCAGGG AACTTGAACA AGCAGCCAGC CTGGACGCCG CCTCCGACCT
1101 GATGGACGGC ACTGATGGCA CTTTTGCTAT GAAGCCTCTG GTACGCCACT
1151 CCGTCGACGC CGTCGGTCTC GATAAGGTTC GTCAGTGCGA GATACACATG
1201 CAGCCGGCGT CCAGGCAGAA CTGCTGCAGG AGCTGGATAA GCAAATTCCC
1251 GACGAGGTCG AAACGCATCG ACGTCATATC AAGAATCACT TTCCCGCTGG
1301 TGTTTGCTTT GTTCAATCTG GTGTACTGGT CGACCTATTT GTTCAGGGAC
1351 GAGGCGGAGG AGAATTAG

FIG.1B

3/8

1 MDSISLLLLL TTCLSLHTCL SANAKPRLGG GKENFRAKEK QVLDQILGPG
51 HYDARIRPSG VNGTGDGPTV VAVNIYLRSI SEIDDYKMEY SVQLTFREQW
101 QDERLKFNDF GGRLKYLTLT EASRVWMPDL FFANEKEGHF HNIIMPVYI
151 RIFPYGSVLY SIRISLTLAC PMNLKLYPLD RQVCSLRMAS YGWTNDLVF
201 LWKEGDPVQV VKNLHLPRFT LEKFLTDYCN SKTNTGEYSC LKVDLLFKRE
251 FSYYLIQIYI PCCMLVIVSW VSFWLDQGAV PARVSLGVTT LLTMATQTSG
301 INASLPPVSY TKAIDVWTGV CLTFVFGALL EFALVNYASR SDMHRENMKK
351 KRRELEQAAS LDAASDLMDG TDGTFAMKPL VRHSVDAVGL DKVRQCEIHM
401 QPASRQNCCR SWISKFPTRS KRIDVISRIT FPLVFALFNL VYWSTYLFRD
451 EAEEN

FIG.2

4/8

1 ATGGACAGCA TTAGTTTGCT CCTACTTTTG ATAACATGTC TAAGTCTACA
51 CACATGCTTA TCTGCAAATG CAAAACCTCG TCTAGGAGGC GGCAAAGAAA
101 ATTTCAGGGC CAAAGAAAAG CAAGTTCTGG ACCAAATTTT AGGCCCAGGC
151 CATTACGATG CCAGAATAAG GCCTTCTGGA GTCAATGGAA CTGGAATACA
201 GTGTCCAGTT AACTTTCAGG GAACAATGGC AGGATGAGAG GTTGAAATTT
251 AACGACTTTG GAGGTCGTTT AAAATACTTA AACTAACCG AAGCAAGTCG
301 TGTATGGATG CCCGATTTGT TCTTTGCGAA TGAAAAGGAG GGCCACTTTC
351 ACAACATCAT CATGCCGAAC GTCTACATTC GTATTTTTC TTACGGTTCC
401 GTACTATACA GCATCAGGAT ATCGCTTACT TTGGCGTGTC CTATGAATCT
451 GAAACTGTAT CCGCTCGATA GGCAGGTGTG CTCTCTCCGG ATGGCCAGTT
501 ATGGTTGGAC CACAAACGAT CTGGTGTTTT TGTGGAAGGA AGGTGACCCG
551 GTGCAGGTTG TCAAGAATCT ACATCTGCCC AGGTTTACGT TGGAGAAGTT
601 CTTGACGGAT TATTGTAACA GCAAAACCAA TACCGGTGAA TACAGTTGCC
651 TGAAGGTGCA CCTGCTCTTT AAACGAGAGT TCTCGTACTA CCTGATCCAG
701 ATCTACATTC CTTGTTGCAT GTTGGTGATC GTTTCCTGGG TGTGTTCTG
751 GTTGGACCAG GGAGCGGTTT CGGCCAGAGT ATCACTGGGT GTGACCACTC
801 TCCTCACCAT GGCCACCCAG ACGTCGGGCA TAAACGCCTC CCTGCCGCCA
851 GTGTCTTACA CAAAAGCCAT CGACGTCTGG ACCGGAGTCT GCCTCACGTT
901 CGTCTTCGGG GCTTTGCTCG AATTGCCCT CGTCAACTAC GCCTCCAGAT

FIG.3A

5/8

951 CCGATATGCA CAGGGAAAAC ATGAAGAAAA AGCGCAGGGA ACTTGAACAA
1001 GCAGCCAGCC TGGACGCCGC CTCGACCTG ATGGACGGCA CTGATGGCAC
1051 TTTTGCTATG AAGCCTCTGG TACGCCACTC CGTCGACGCC GTCGGTCTCG
1101 ATAAGGTTTCG TCAGTGCGAG ATACACATGC AGCCGGCGTC CAGGCAGAAC
1151 TGCTGCAGGA GCTGGATAAG CAAATTCCCG ACGAGGTCGA AACGCATCGA
1201 CGTCATATCA AGAATCACTT TCCCGCTGGT GTTTGCTTTG TTCAATCTGG
1251 TGTACTGGTC GACCTATTTG TTCAGGGACG AGGCGGAGGA GAATTAG

FIG.3B

1 MDSISLLLLL ITCLSLHTCL SANAKPRLGG GKENFRAKEK QVLDQILGPG
51 HYDARIRPSG VNGTGIQCPV NFQGTNAG

FIG.4

6/8




FIG.5A




FIG.5B

7/8




FIG.6

8/8




FIG.7A




FIG.7B

SEQUENCE LISTING

<110> Merck & Co., Inc.

<120> DNA MOLECULES ENCODING CTENOCEPHALIDES
FELIS GLUTAMATE GATED CHLORIDE CHANNELS

<130> 20029

<160> 8

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 1368

<212> DNA

<213> ctenocephalides felis

<400> 1

atggacagca	ttagtttgct	cctacttttg	ataacatgtc	taagtctaca	cacatgctta	60
tctgcaaata	caaaacctcg	tctaggaggc	ggcaaagaaa	atttcagggc	caaagaaaag	120
caagttctgg	accaaatttt	aggcccaggc	cattacgatg	ccagaataag	gccttctgga	180
gtcaatggaa	ctggagacgg	tccgaccgtg	gtagcagtc	acatctatct	gagatcaatc	240
agcgaaatag	atgactacaa	aatggaatac	agtgtccagt	taactttcag	ggaacaatgg	300
caggatgaga	ggttgaaatt	taacgacttt	ggaggtcgtt	taaaatactt	aacactaacc	360
gaagcaagtc	gtgtatggat	gcccgaattg	ttctttgcga	atgaaaagga	gggccacttt	420
cacaacatca	tcatgccgaa	cgtctacatt	cgtatttttc	cttacgggtc	cgtactatac	480
agcatcagga	tatcgcttac	tttggcgtgt	cctatgaatc	tgaaactgta	tccgctcgat	540
aggcaggtgt	gctctctccg	gatggccagt	tatggttgga	ccacaaacga	tctggtgttt	600
ttgtggaagg	aaggtgaccc	ggtgcaggtt	gtcaagaatc	tacatctgcc	caggtttacg	660
ttggagaagt	tcttgacgga	ttattgtaac	agcaaaacca	ataccggtga	atacagttgc	720
ctgaaggtcg	acctgctctt	taaacgagag	ttctcgtact	acctgatcca	gatctacatt	780
ccttgttgca	tgttggtgat	cgtttcctgg	gtgtcgttct	ggttggaacca	gggagcgggt	840
ccggccagag	tatcactggg	tgtgaccact	ctcctcacca	tggccaccca	gacgtcgggc	900
ataaacgcct	cctgcccgc	agtgtcctac	acaaaagcca	tcgacgtctg	gaccggagtc	960
tgccctcact	tcgtcttcgg	ggctttgtct	gaattcgccc	tcgtcaacta	cgcctccaga	1020
tccgatatgc	acagggaaaa	catgaagaaa	aagcgcaggg	aacttgaaca	agcagccagc	1080
ctggacgcgc	cctccgacct	gatggacggc	actgatggca	cttttgctat	gaagcctctg	1140
gtacgccact	ccgtcgacgc	cgtcggtctc	gataaggttc	gtcagtgcca	gatacacatg	1200
cagccggcgt	ccaggcagaa	ctgctgcagg	agctggataa	gcaaattccc	gacgaggtcg	1260
aaacgcacgc	acgtcatatc	aagaatcact	ttcccgtcgg	tgtttgcttt	gttcaatctg	1320
gtgtactggt	cgacctatct	gttcagggac	gaggcggagg	agaattag		1368

<210> 2

<211> 455

<212> PRT

<213> ctenocephalides felis

<400> 2

Met	Asp	Ser	Ile	Ser	Leu	Leu	Leu	Leu	Ile	Thr	Cys	Leu	Ser	Leu
1			5					10					15	
His	Thr	Cys	Leu	Ser	Ala	Asn	Ala	Lys	Pro	Arg	Leu	Gly	Gly	Lys
			20					25					30	
Glu	Asn	Phe	Arg	Ala	Lys	Glu	Lys	Gln	Val	Leu	Asp	Gln	Ile	Leu
			35					40					45	

Pro Gly His Tyr Asp Ala Arg Ile Arg Pro Ser Gly Val Asn Gly Thr
 50 55 60
 Gly Asp Gly Pro Thr Val Val Ala Val Asn Ile Tyr Leu Arg Ser Ile
 65 70 75 80
 Ser Glu Ile Asp Asp Tyr Lys Met Glu Tyr Ser Val Gln Leu Thr Phe
 85 90 95
 Arg Glu Gln Trp Gln Asp Glu Arg Leu Lys Phe Asn Asp Phe Gly Gly
 100 105 110
 Arg Leu Lys Tyr Leu Thr Leu Thr Glu Ala Ser Arg Val Trp Met Pro
 115 120 125
 Asp Leu Phe Phe Ala Asn Glu Lys Glu Gly His Phe His Asn Ile Ile
 130 135 140
 Met Pro Asn Val Tyr Ile Arg Ile Phe Pro Tyr Gly Ser Val Leu Tyr
 145 150 155 160
 Ser Ile Arg Ile Ser Leu Thr Leu Ala Cys Pro Met Asn Leu Lys Leu
 165 170 175
 Tyr Pro Leu Asp Arg Gln Val Cys Ser Leu Arg Met Ala Ser Tyr Gly
 180 185 190
 Trp Thr Thr Asn Asp Leu Val Phe Leu Trp Lys Glu Gly Asp Pro Val
 195 200 205
 Gln Val Val Lys Asn Leu His Leu Pro Arg Phe Thr Leu Glu Lys Phe
 210 215 220
 Leu Thr Asp Tyr Cys Asn Ser Lys Thr Asn Thr Gly Glu Tyr Ser Cys
 225 230 235 240
 Leu Lys Val Asp Leu Leu Phe Lys Arg Glu Phe Ser Tyr Tyr Leu Ile
 245 250 255
 Gln Ile Tyr Ile Pro Cys Cys Met Leu Val Ile Val Ser Trp Val Ser
 260 265 270
 Phe Trp Leu Asp Gln Gly Ala Val Pro Ala Arg Val Ser Leu Gly Val
 275 280 285
 Thr Thr Leu Leu Thr Met Ala Thr Gln Thr Ser Gly Ile Asn Ala Ser
 290 295 300
 Leu Pro Pro Val Ser Tyr Thr Lys Ala Ile Asp Val Trp Thr Gly Val
 305 310 315 320
 Cys Leu Thr Phe Val Phe Gly Ala Leu Leu Glu Phe Ala Leu Val Asn
 325 330 335
 Tyr Ala Ser Arg Ser Asp Met His Arg Glu Asn Met Lys Lys Lys Arg
 340 345 350
 Arg Glu Leu Glu Gln Ala Ala Ser Leu Asp Ala Ala Ser Asp Leu Met
 355 360 365
 Asp Gly Thr Asp Gly Thr Phe Ala Met Lys Pro Leu Val Arg His Ser
 370 375 380
 Val Asp Ala Val Gly Leu Asp Lys Val Arg Gln Cys Glu Ile His Met
 385 390 395 400
 Gln Pro Ala Ser Arg Gln Asn Cys Cys Arg Ser Trp Ile Ser Lys Phe
 405 410 415
 Pro Thr Arg Ser Lys Arg Ile Asp Val Ile Ser Arg Ile Thr Phe Pro
 420 425 430
 Leu Val Phe Ala Leu Phe Asn Leu Val Tyr Trp Ser Thr Tyr Leu Phe
 435 440 445
 Arg Asp Glu Ala Glu Glu Asn
 450 455

<210> 3
 <211> 1297
 <212> DNA

<213> ctenocephalides felis

<400> 3

atggacagca	ttagtttgc	cctacttttg	ataacatg	taagtctaca	cacatgctta	60
tctgcaa	aatg caaaac	ctcg tctag	ggcagg	gcaagaaa	atctcaggg	120
caagttctg	g accaaat	ttt agggcc	cagg cctac	gatg ccaga	ataag gcctt	180
gtcaatgg	aa ctgga	ataca gtgtc	cagtt aactt	tcagg gaaca	atggc aggat	240
gttgaaat	ttt aacga	ctttg gaggt	cgttt aaa	atactta acact	aaccg aagca	300
tgtatgg	atg cccga	ttttg tctt	tgcga tgaaa	aggag ggcca	ctttc acaac	360
catgccga	ac gtctac	attc gtatt	tttcc ttacc	ggttcc gtact	tataca gcat	420
atcgctta	ct ttggc	gtgt ctat	gaatct gaa	actgtat ccg	ctcgata gg	480
ctctctcc	gg atggc	cagtt atggt	tggac caca	aacgat ctg	gtgtttt	540
aggtgacc	cg gtgcag	gttg tca	aagatct acat	ctgccc aggt	tttacgt	600
cttgacgg	at tattg	taaca gcaaa	accaa tacc	ggtgaa tac	agttgcc	660
cctgctct	ttt aaacg	agagt tctc	gtacta cct	gatccag atct	acattc	720
gttggtga	tc gtttc	ctggg tgct	gtctg gtt	ggaccag ggag	cgggttc	780
atcactgg	gt gtgacc	tc tccacc	at ggccac	ccag acgt	cgggca	840
cctgccgc	ca gtgtc	ctaca caaa	agccat cgac	gtctgg acc	ggagtct	900
cgctctcg	gg gcttt	gctcg aatt	cgcct cgt	caactac gcct	ccagat	960
cagggaaa	ac atga	aaaaa agcg	cagggaa act	tgaacaa gcag	ccagcc	1020
ctccgac	ctg atgg	acggca ctga	tggcac ttt	gtctatg aag	cctctgg	1080
cgctgac	gcgc gtc	gtctc ata	aaggttc tcag	tgcgag atac	acatgc	1140
caggcaga	aac tgcag	ga gctgg	ataag caa	attccc acg	aggtcga	1200
cgctatat	ca aga	tcact tccc	gctggt gtt	gtctttg ttca	atctgg	1260
gacctatt	tg ttcag	gggacg aggc	ggagga ga	attag		1297

<210> 4

<211> 78

<212> PRT

<213> ctenocephalides felis

<400> 4

Met	Asp	Ser	Ile	Ser	Leu	Leu	Leu	Leu	Ile	Thr	Cys	Leu	Ser	Leu
1				5					10				15	
His	Thr	Cys	Leu	Ser	Ala	Asn	Ala	Lys	Pro	Arg	Leu	Gly	Gly	Lys
			20					25				30		
Glu	Asn	Phe	Arg	Ala	Lys	Glu	Lys	Gln	Val	Leu	Asp	Gln	Ile	Leu
			35				40				45			
Pro	Gly	His	Tyr	Asp	Ala	Arg	Ile	Arg	Pro	Ser	Gly	Val	Asn	Gly
			50				55				60			
Gly	Ile	Gln	Cys	Pro	Val	Asn	Phe	Gln	Gly	Thr	Met	Ala	Gly	
65					70					75				

<210> 5

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<400> 5

ctcagagtca ggcacggct a

21

<210> 6

<211> 21

<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 6
ctgaaagtta actggacact g 21

<210> 7
<211> 751
<212> DNA
<213> ctenocephalides felis


<400> 7
aactagtgga tcccccgggc tgcaggattc ggcacgagaa ttttttaaaa taatcctcaa 60
cagcatgata caagaggatg attttatgat ccctgtaaac acttgcttga attttagatt 120
gcaactggag gctccgctga cactctctct tgttcgagca caggaattgc tcgacatctg 180
gtcaaacgcg ggctacttca taatatccga cgatgacaat ttaatgttcg gagcaagaac 240
aattgcagaa tttgaagtgt actttaacga tacattcgaa ggacgcatga aaatgtgcac 300
gatgtgcatg ttccccacct tctattgacc agcaagcacc ccttcgccgg tgagcatgtc 360
accacccgac aggcgccttc tgtgcgcctt cgacgacctg cacttagcgg ttgctaagaa 420
gccctaagaa gccgagacgg ttcgcttcgc ccggggggcga ttccctcacga tgcacaagcg 480
gaggcgcaag aggctgacga cgaggagcct cagagtcagg atccggctat attggacgat 540
atgctgcatg gtccctgtca tacaataact ccttcgcctt cactggaacc aaccaagact 600
gtccccacgt gtccgacatc agttgaagga aattctgtga cgacatggca acacttttgt 660
tcaggaacaa caataacatc atcgacacag aatatcggcg aagcctattc ttcgattcaa 720
gaagaagaat ttcttcactt tatcttcagg g 751

<210> 8
<211> 532
<212> DNA
<213> ctenocephalides felis

<400> 8
tcagagtcag gatccggcta tattggacga tatgtgtcat ggtccctgtc atacaaatac 60
tccttcgcct tcaactggaac caaccaagac tgtccccacg tgtccgacat cagttgaagg 120
aaattctgtg acgacatggc aacacttttg ttcaggaaca acaataacat catcgacaca 180
gaatatcggc gaagcctatt ctctgattca agaagaagaa tttcttcact ttatcttcag 240
ggatggacag cattagtttg ctctactttt tgataacatg tctaagtcta cacacatgct 300
tatctgcaaa tgcaaaacct cgtctaggag gcggcaaaga aaatttcagg gccaaagaaa 360
agcaagttct ggaccaaatt ttaggcccag gccattacga tgccagaata aggccttctg 420
gagtcaatgg aactggagac ggtccgaccg tggtagcagt caacatctat ctgagatcaa 480
tcagcgaaat agatgactac aaaatggaat acagtgtcca gttaactttc ag 532

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/16613

A. CLASSIFICATION OF SUBJECT MATTER IPC(6) : C12N 1/20, 15/00; C07H 21/04 US CL : 435/7.1, 7.2, 69.1, 240.2, 252.3, 252.33, 320.1; 536/23.5 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 435/7.1, 7.2, 69.1, 240.2, 252.3, 252.33, 320.1; 536/23.5 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) APS and DIALOG (files 5, 155, 351, 357, 358) search terms: ctenocephalides, felis, glutamate, chloride, channel, gated, cat, flea		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A, P	US 5,693,492 A (CULLY et al) 02 December 1997, see entire document.	1-34
A	CULLY et al. Identification of a Drosophila melanogaster glutamate-gated chloride channel sensitive to the antiparasitic agent avermectin. Journal of Biological Chemistry. 16 August 1996, Vol. 271, No. 33, pages 20187-20191, see entire document.	1-34
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* *A* *E* *L* *O* *P*	Special categories of cited documents: document defining the general state of the art which is not considered to be of particular relevance earlier document published on or after the international filing date document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed	*T* *X* *Y* *A* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art document member of the same patent family
Date of the actual completion of the international search 23 SEPTEMBER 1998		Date of mailing of the international search report 20 OCT 1998
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer  MARIANNE P. ALLEN Telephone No. (703) 308-0196